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ABSTRACT 
Progress in disseminating and implementing evidence-based psychological 
treatments (EBPTs) has been gradual.  To date, the dominant target for promoting EBPTs 
in clinical settings has been the education and training of mental health providers, with 
many consumers remaining unaware of EBPTs’ potential benefits.   
The present study empirically evaluated via a randomized controlled design the 
preliminary utility of direct-to-consumer (DTC) advertising of psychological treatments 
(PTs).  American and Canadian undergraduate participants (N=344) were randomly 
assigned to view one of four commercial campaigns via the Internet on three occasions.  
Each campaign consisted of three different commercials embedded within unrelated 
content.  Campaign content varied across participants, who were assigned to either the [1] 
Psychological Treatment (PT) campaign (n=98); [2] Psychological Treatment informing 
about Medication Side Effects (PT-MSE) campaign (n=80); [3] Medication (MED) 
campaign (n=82); or [4] the Neutral (NEU; i.e., control) campaign (n=84).  The groups 
did not differ significantly on age or gender distribution.  Data regarding attitudes about 
 vii 
psychological treatment and treatment-seeking behaviors were collected prior to the 
intervention (T1), one week following the intervention (T2), and at a three-month follow-
up evaluation (T3).  It was hypothesized that those in the PT and PT-MSE conditions 
would have improved attitudes about psychological treatment and increased rates of 
seeking psychological treatment compared to those assigned to MED and NEU. 
The percentage of participants who newly intended psychological treatment at T2 
or T3 differed by condition, with PT-MSE participants significantly more likely to have 
considered receiving psychological treatment than those in the other conditions. Those in 
PT were significantly more likely to have planned to receive psychological treatment at 
T2 or T3 than those in the other conditions.  MED participants, as compared to 
participants in the other conditions, reported significantly increased levels of comfort 
about psychopharmacological treatment at T3.  Baseline reports of DSM-IV 
symptomatology, stigma toward psychological treatments, media consumption, and 
nationality all significantly moderated various outcomes related to attitudes toward 
psychopharmacological and psychological treatment.   
The present study provides supporting evidence of the preliminary utility and 
efficacy of DTC marketing of PTs, suggesting that increasing consumer knowledge of 
PTs may be a worthwhile augmentation to EBPT dissemination and implementation 
efforts. 
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Direct-to-Consumer Marketing of Psychological  
Treatments: A Randomized Controlled Trial 
In recent decades, psychological treatments have been developed and 
demonstrated considerable efficacy in the treatment of several mental disorders (Nathan 
& Gorman, 2007; NICE, 2009; Roth & Fonagy, 2005). Despite the prevalence and 
reduced quality of life associated with mental disorders (Comer, Blanco, et al., 2011; 
Kessler, Berglund, et al., 2005; Rapaport, Clary, Fayyad, & Endicott, 2005) in research 
settings up to two-thirds of individuals receiving supported psychological treatments 
show considerable clinical response and global improvements in functioning. 
Accordingly, researchers and policymakers alike are making a substantial push to 
disseminate and implement evidence-based practices (EBPs) and evidence based 
psychological treatments (EBPTs) into healthcare delivery systems.  Despite calls for 
changes in service delivery, progress disseminating and implementing EBPTs and EBPs 
has been gradual (Beidas & Kendall, 2010; Herschell, McNeil, & McNeil, 2004; 
McHugh & Barlow, 2010; see also Comer & Barlow, in press).   
Regrettably, despite the existence of well-supported treatments, most individuals 
with emotional disorders do not receive any form of treatment (Kessler, Demler, et al., 
2005), and for those who do seek care, the delay between disorder onset and service 
utilization is substantial—averaging up to 8 years for mood disorders and up to 23 years 
for anxiety disorders (Wang et al., 2005).  For example, only 3% of individuals with 
social anxiety disorder (SAD) seek treatment within their first year of SAD onset, and 
among individuals who do eventually seek care, the median delay between disorder onset 
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and treatment initiation is 16 years (Wang et al., 2005).  Dissemination efforts 
exclusively targeting the education and training of mental health providers may do little 
to promote EBPT participation among affected individuals who do not even present for 
treatment.  Indeed, poor service initiation and utilization among individuals affected by 
mental disorders may be related, in part, to a general lack of awareness across the general 
population that the majority of mental disorders can be highly treatable.   
The regrettably small proportion of individuals in treatment for mental disorders 
actually receiving guideline-concordant care (Hogan, 2003; Wang, Berglund, & Kessler, 
2000) may be due in part to clinicians underutilizing psychological treatments in their 
practices.  For primary care physicians and psychiatrists, the vacuum of quality referral 
options for psychological treatments may place heavy clinical demands on the 
pharmacologic dimensions of patients’ mental health care.  Despite the existence of 
effective psychological treatments for mental disorders and research showing that 
patients tend to prefer psychological treatments over pharmaceutical treatments 
(McHugh, Whitton, Peckham, Welge, & Otto, in press), in recent years medication as 
monotherapy has become increasingly prevalent in outpatient child and adult mental 
health settings (44.1% of patients in outpatient mental health care in 1998 versus 57.4% 
in 2007) and psychological treatments have assumed a diminished role in mental health 
care (with total expenditures for psychotherapy in the United States decreasing by over 
$3 billion during that nine year period; Olfson & Marcus, 2010).  In fact, recent reports 
document increasing national trends in the use of off-label psychotropic regimens with 
unfavorable side effect profiles to treat mental disorders for which established but 
3 
 
underutilized psychosocial treatments exist (Comer, Mojtabai, & Olfson, 2011; Olfson, 
Crystal, Huang, & Gerhard, 2010).  For example, the rate of antipsychotic prescriptions 
for anxiety disorders doubled in recent years, and currently 1 in 5 outpatient psychiatry 
visits for an anxiety disorder results in prescription of an antipsychotic medication 
(Comer, Mojtabai, & Olfson, 2011).  These trends are particularly concerning, given that 
these increasingly common psychotropic regimens are associated with a host of 
unfavorable side effects, including metabolic and cerebrovascular effects, and they are 
not approved by the United States Food and Drug Administration (FDA) for the 
management of some of the disorders for which they are being used to treat.  In addition 
to the efficacy of PTs, they are more cost-effective than medication in many cases 
(Heuzenroeder et al., 2004).  To some degree, the increasingly common off-label 
psychotropic management of mental disorders may reflect an under-informed general 
population of individuals with mental disorders who are unaware of the tremendous 
advances in psychological intervention science for the management of mental disorders.   
For example, cognitive behavioral therapies (CBTs) have demonstrated 
considerable efficacy in treating a number of mental disorders, including panic disorder, 
generalized anxiety disorder, depression, and post-traumatic stress disorder, to name a 
few (Butler, Chapman, Forman, & Beck, 2006).  Accordingly, published clinical practice 
guidelines put forth by various agencies (e.g., the National Institute for Health and 
Clinical Excellence [NICE] in the United Kingdom and the Agency for Health Care 
Research and Quality [AHRQ] in the United States) recommend the use of CBT as a first 
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line treatment for several disorders (e.g., Fiore, 2000; Kendall, Pilling, Whittington, 
Pettinari, & Burbeck, 2005).   
Collectively, such findings underscore a renewed sense of urgency for innovative 
methods to accelerate the flow of affected individuals into effective care.  However, 
despite the push by researchers and policymakers for increased use of EBPTs and EBPs, 
and the existence of consensus treatment guidelines characterizing psychological 
treatments as first-line treatments for many of the most prevalent mental health 
conditions, EBPTs remain the exception, rather than the rule, in mental health service 
delivery in the United States.  
To date, the dominant approach for advancing the increased use of evidence based 
psychological treatments has been to target mental health providers.  Dissemination 
researchers, treatment developers, and, in some cases, government agencies, have 
provided mental health clinicians with data, expert treatment guidelines, and specialized 
trainings in an attempt to increase the use of evidence-based psychological treatments, 
with some of these efforts showing good success (e.g., Linehan, Manning, & Ward-
Ciesielski, 2008; Resick, Foa, Ruzek, & Karlin, 2008; Schoenwald, Heiblum, Saldana, & 
Henggeler, 2008).  Other data on the success of dissemination efforts targeting mental 
health providers have been less encouraging, particularly when typical training methods 
(e.g., workshops, manuals, and supervision) are used without ongoing active learning 
methods, such as coaching and feedback (see Beidas & Kendall, 2010). Importantly, 
despite considerable attention and substantial funding devoted to large-scale 
dissemination efforts (McHugh & Barlow, 2010) to date a sizable gap remains between 
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outcomes in controlled research settings and in clinical practice settings (Stewart & 
Chambless, 2007; see also Kendall, Hudson, Gosch, Flannery-Schroeder, & Suveg, 2008 
versus Weisz, et al., 2009) and most individuals treated for mental disorders are not 
receiving evidence-based care (e.g., Becker, Zayfert, & Anderson, 2004; Young, Klap, 
Sherbourne, & Wells, 2001).  The focus of these large dissemination efforts to date 
reveals an implicit assumption that the primary barrier to the use of evidence-based 
psychological treatments is an insufficient number of providers with the necessary 
knowledge and training.  Substantial resources, time, and money are spent training 
professionals on a mass scale, but the methods used in many of these efforts lack 
supporting data.   
One infrequently discussed barrier to the implementation of evidence based 
psychological treatments is a simple lack of consumer knowledge about the potential 
benefits of psychological treatments (Carman et al., 2010), with most consumers unaware 
of their potential benefits.  Owens and colleagues’ study of barriers to care (2002) 
showed that sizable proportions of potential consumers do not know where to get help, 
and do not believe treatment can help them.  The current dominant model for advancing 
psychological treatments, which focuses solely on targeting professionals, insufficiently 
addresses these important systematic barriers to care.  This almost exclusively “top-
down” focus on providers in ongoing dissemination efforts reflects an implicit 
assumption that the primary barrier to the use of EBPTs is an insufficient number of 
providers with the necessary knowledge, training, and competency.  This is likely true, 
but these “top down” efforts alone will be insufficient to address key concerns that affect 
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initial treatment-seeking behaviors among consumers and similarly interfere with EBPT 
participation.  	  
In contrast, direct-to-consumer (DTC) marketing has a long and successful history 
in the United States’ pharmaceutical industry, with the first advertisement for medication 
published in a newspaper in the early eighteenth century (Bhanji et al., 2008).  Today, 
DTC marketing of pharmaceuticals is fully legal only in the United States and New 
Zealand, where it is practiced across drug classes, with drugs for mental disorders 
comprising three of the top five categories of most frequently prescribed drugs in the U.S. 
(i.e., antidepressants, antipsychotics, and anticonvulsants; Bhanji et al., 2008).  Given the 
proliferation of advertisements for psychopharmacological interventions in recent years, 
Americans are much more likely to learn about the utility of medications in the treatment 
of mental disorders than about psychological treatments that are of equal or greater 
efficacy, and are linked with more favorable side effect profiles.  
Importantly, there is evidence that DTC marketing of pharmaceutical 
interventions can change both patient treatment-seeking behavior and physician behavior.  
For example, DTC marketing of medications is associated with increased requests for 
specific drugs by patients (Gilbody, Wilson, & Watt, 2005) and has been named as a 
motivator for patients to learn about medical conditions or the medications used to treat 
them (Aikin, Swasy, & Braman, 2004).  A 2002 FDA survey found that 43 percent of 
people who saw advertisements for prescription medications then sought out more 
information about the content of the advertisements (Aikin et al., 2004).  Another survey 
found that 31 percent of those who consumed DTC advertising then wanted to talk with 
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their doctor about what they had seen (Friedman & Gould, 2007; citing Golodner, 2003).  
One study found that DTC advertising about antidepressant medication promoted 
discussion of the medication with one’s doctor (Bell, Taylor, & Kravitz, 2010)  In 
another study comparing prescription rates in Canada –where DTC advertising is only 
permitted in a highly regulated format—and in the United States, individuals who were 
exposed to more advertisements requested more medication, and were subsequently 
prescribed more medication, than those who were exposed to fewer advertisements 
(Mintzes et al., 2003). 
In addition to changing patient behavior, DTC marketing is associated with 
changes in physician behavior, with increases in prescriptions of advertised products, as 
well as increased diagnoses of the disorders treated by advertised medications (Gilbody et 
al., 2005).  In one study, for example, actors portraying patients in physicians’ offices 
asked physicians about antidepressant medication, and antidepressant prescription rates 
increased relative to doctors who were visited by “patients” (portrayed by actors) who did 
not ask physicians about antidepressant medications (Kravitz et al., 2005).  
Importantly, while DTC marketing could translate into more people getting 
treatments they need, it could also result in more individuals being prescribed drugs that 
they do not need, or drugs that may in fact be contraindicated. Despite the success of 
DTC marketing for pharmacologic interventions, the practice is certainly not without 
controversy, with critics claiming that the pharmaceutical industry may be seeking to 
increase psychotropic drug use even among individuals who may not need intervention 
(Moynihan & Cassels, 2005).  Concerns about overly broad or vague marketing 
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campaigns have been well documented (e.g., Spielmans, Thielges, Dent, & Greenberg, 
2008).  Alongside increases in DTC marketing of psychotropic medications, in recent 
years prescription rates have increased steadily, including regimens for which safety has 
not been established (e.g., Comer, Olfson, & Mojtabai, 2010), while use of psychological 
treatments has steadily played a decreasingly prominent role in mental health care 
(Mojtabai & Olfson, 2008; Olfson & Marcus, 2010).  In many cases, DTC marketing 
increases awareness of medications whose benefits outweigh the risks, but this is not 
always the case (e.g., Spielmans & Parry, 2010).  For some promoted regimens, 
consumers might experience more negative side effects than positive benefit.  
Additionally, critics of DTC advertising contend that advertisements are positively 
biased, create too much demand for expensive drugs, and negatively affect the doctor-
patient relationship (Gilbody et al., 2005).  On balance, whereas DTC marketing can 
promote overprescription when broadly or vaguely applied, when applied appropriately 
the practice can increase consumer knowledge of available interventions among suffering 
individuals when firmly grounded in empirical support.  This DTC tradeoff is a source of 
continued contention (Kravitz & Bell, 2007; Kravitz et al., 2005; Moynihan & Cassels, 
2005; Wolfe, 2002).   
Meanwhile, for many conditions for which psychotropic interventions with 
potential deleterious side effects are aggressively and successfully marketed, it is possible 
that psychosocial treatment methods would be of equal or greater efficacy, and without 
associated adverse events (e.g., Butler et al., 2006).  Disproportionate DTC marketing 
efforts across psychotropic and psychological treatments may leave consumers relatively 
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unaware of the considerable efficacy of many psychological treatments for mental 
disorders.  For example, sizable proportions of parents report holding negative 
perceptions of mental health and mental health services (Owens et al., 2002) and negative 
views about the effectiveness of treatment for depression are a primary barrier to low 
rates of depression treatment for affected young adults (Van Voorhees et al., 2005).  For 
many affected individuals, incorrect assumptions about potential treatment benefits may 
interfere with obtaining services.  A suffering individual misinformed by outdated 
summaries of the utility of psychological treatments (e.g., Eysenck, 1952) is unlikely to 
pursue psychological treatment.  Among individuals who do seek psychological 
treatment, faulty assumptions, such as a belief that all psychological treatments and their 
empirical support for various conditions are comparable, may misdirect affected 
individuals toward treatments that lack empirical support.  Faulty assumptions about the 
comparability of all forms of psychotherapy and psychological treatments can be 
perpetuated by poorly specified media reports of treatment research.  For example, after 
the landmark multisite CAMS trial (Child/Adolescent Anxiety Multimodal Study; 
Walkup et al., 2008) found that a specific combination of CBT (Coping Cat Program; 
Kendall & Hedtke, 2006) and antidepressant medication was associated with clinical 
response in 80% of children with anxiety disorders, the New York Times article reporting 
on the study’s findings was headed with the very unspecific title “Combination of talk 
therapy and medicine is found to ease anxiety in children.”  It is highly unlikely that a 
combination of any given “talk therapy” with any given “medicine” will yield 80% 
response rates.  Participation in unsupported treatments can result in poor treatment 
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response, which can further public misperceptions about the potential utility of 
psychological treatments.  Moreover, research shows that positive patient expectancies 
about treatment response are actually associated with improved outcomes (Lewin, Peris, 
Bergman, McCracken, & Piacentini, 2011; Newman & Fisher, 2010).  Therefore, not 
only can misinformation about the utility of psychological treatment interfere with initial 
treatment-seeking, but among those who do seek appropriate care such misinformation 
may also impact the actual success of treatment.   
While attitudes about receiving mental health treatment have somewhat improved 
across the last 20 years (Mojtabai, 2007), perceived stigma toward receiving treatment for 
mental disorders may still prevent many people from accessing treatment.  In the United 
States, one in four surveyed mental health consumers reported feeling stigmatized (Wahl, 
1999).  This number may presumably be even higher for those with mental disorders who 
have not yet sought treatment.  Perceived stigma may also be one of the factors delaying 
individuals in need of treatment for a mental disorder from seeking care (Rüsch, 
Angermeyer, & Corrigan, 2005; Thornicroft, 2012) and high levels of stigma in the 
general population are associated with self-stigma in people with mental illness (Evans-
Lacko, Brohan, Mojtabai, & Thornicroft, 2012). Racial and ethnic minorities may be 
particularly likely to express concerns about discrimination (Williams, Domanico, 
Marques, Leblanc, & Turkheimer, 2012). 
Amidst the debate and controversy, the greatest potential benefit from of DTC 
marketing is for treatments that are (1) safe, (2) proven effective, and (3) underutilized 
for serious conditions (Almasi, Stafford, Kravitz, & Mansfield, 2006).  Relative to many 
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of the pharmacotherapy regimens currently advancing, which can in several 
circumstances come with risk of unfavorable side effects, psychological treatments 
certainly meet these three criteria.  However, the literature lacks empirical investigation 
of the potential effects of DTC marketing for psychological treatments (see Gallo, 
Comer, & Barlow, in press).  Given the impressive results seen in the pharmaceutical 
industry with regard to affecting attitudes and treatment-seeking behavior, DTC 
marketing may be a promising vehicle to increase psychological treatments utilization 
rates.  Marketing of psychological treatments directly to potential consumers is largely 
unchartered territory, but could increase the demand for psychological treatments.  
Specifically, as consumers become aware of the benefits of psychological treatments, 
they may be more likely to discuss it with their providers and to seek out such services, 
thus increasing the demand for effective psychological treatments.  Moreover, early 
symptoms of mental disorders tend to be poorly recognized (Thornicroft, 2006).  
Educating the public about the symptoms of mental disorders and effective methods of 
treatment could result in increased knowledge and improved attitudes about mental 
illness and treatment, underscoring a potential need for public education campaigns.  
However, the effect of such educational campaigns on treatment-seeking behavior is not 
yet well understood.   
Collectively, this current state of affairs underscores a sense of urgency to inform 
potential consumers on a broad scale of the potential benefits of psychological 
treatments. Given the tremendous success of DTC marketing efforts in the promotion of 
pharmaceutical products, in addition to important and ongoing efforts targeting the broad 
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dissemination of supported psychological treatments to providers, there may be an 
important and complementary role for the DTC marketing of psychological treatments.  
While dissemination efforts are essential to optimizing the quality of services offered in 
practice settings, complementary “bottom-up” DTC strategies may be invaluable for 
promoting initial treatment-seeking behavior and for specifically directing the flow of 
treatment-seeking individuals toward settings offering supported psychological 
treatments.  Rather than spending all available resources educating professionals, 
involving the consumer more explicitly is another potential avenue for dissemination 
efforts.  Educating potential consumers in a bottom-up approach could presumably lead 
those educated consumers to seek out psychological treatments when in need of mental 
health services, thus creating a demand for more professionals to be trained in and 
provide psychological treatments. 
Summary of Aims and Hypotheses of the Present Study 
 Broadly speaking, the present study empirically evaluated via a randomized 
controlled design the preliminary utility of DTC advertising of psychological treatments.  
American and Canadian undergraduate participants were randomly assigned either to a 
control condition or to view one of three series of three different 30-second commercials 
embedded within unrelated viewing content over the course of three viewing periods (for 
a total of nine study advertisements viewed).  DTC advertising for medication is highly 
regulated in Canada, and so Canadian participants are presumably relatively naïve to the 
sort of DTC marketing for medication that is ubiquitous in American media.  The content 
of these nine commercials varied across participants.  Specifically, participants were 
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randomly assigned to consume either the: [1] psychological treatments campaign (PT; 
e.g., the “Psychotherapy can help” campaign); [2] psychological treatments + medication 
side effects campaign (PT-MSE; e.g., the “Psychotherapy works without side effects” 
campaign); [3] medication campaign (MED; e.g., “many medications can help you feel 
better”); or [4] Neutral campaign, consisting of commercials unrelated to mental health 
[NEU].  Data regarding attitudes about psychological treatment and treatment-seeking 
behaviors were collected prior to the intervention (T1), one week following the 
intervention (T2), and at a three-month follow-up evaluation (T3).  
Several hypotheses were tested in this study.  Specific aims and hypotheses are 
listed below. 
Aim 1 
 The primary aim of this project was to investigate the effects of direct-to-
consumer (DTC) marketing for psychological treatments on intended and actual 
psychological treatment-seeking behavior. 
Hypothesis 1 
 It was hypothesized that compared to the groups of individuals assigned to MED 
and NEU, those assigned to the psychological treatment marketing campaigns (PT and 
PT-MSE participants) would report increased rates of considering psychological 
treatment, intended psychological treatment-seeking, as well as increased frequency of 
actually obtaining psychological treatments for themselves or someone else, at T2 and/or 
T3. 
Aim 2 
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 The secondary aim was to evaluate potential moderators of the associations 
between campaign assignment and intended and actual treatment-seeking behavior. 
Hypothesis 2 
It was hypothesized that reported stigma-related beliefs and DSM-IV 
symptomatology at baseline would each moderate the relationships between DTC 
campaign assignment and intended and actual treatment-seeking behavior.  Specifically, 
it was hypothesized that increased associations between the PT campaigns (relative to 
MED and NEU) and intended and actual psychological treatment-seeking behavior would 
be strongest among individuals with lower stigma-related beliefs and higher 
symptomatology at T1, because these individuals are presumably more likely to be open 
to the idea of psychological treatment at baseline.  Country and media consumption were 
also examined as moderators, with experimental effects, particularly for the MED 
condition, hypothesized to be stronger among Canadian participants who are theoretically 
relatively naïve to DTC marketing of medications compared to their American 
counterparts.  
Aim 3 
The third aim was to investigate the effects of the PT marketing campaigns on 
self-reported attitudes towards psychological and pharmacological treatments, as well as 
key moderators of these effects.   
Hypothesis 3 
 It was hypothesized that compared to groups of individuals in the MED and NEU 
campaigns, respectively, those assigned to the PT campaigns (i.e., PT and PT-MSE) 
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would show increased self-reported positive attitudes toward psychological treatments.  It 
was also hypothesized that reported stigma-related beliefs and DSM-IV symptomatology 
at baseline would each moderate relationships between campaign assignment and 
attitudes about psychological treatments; specifically, that the increased association 
between the PT campaigns (relative to MED and NEU) and positive attitudes about 
psychological treatments would be strongest among individuals with lower stigma-related 
beliefs and higher symptomatology at T1, because these individuals are presumably more 
likely to be open to the idea of psychological treatment at baseline.  It was also 
hypothesized that those assigned to the MED campaign would show increased self-
reported positive attitudes toward psychopharmacological treatments compared to those 
in the other three conditions.  The increased association between the MED campaigns 
(relative to the other three campaigns) and positive attitudes about 
psychopharmacological treatments was hypothesized to be strongest among individuals 
with lower stigma-related beliefs and higher symptomatology at baseline.  Country and 
media consumption were also examined as moderators, with experimental effects 
hypothesized to be stronger among Canadian participants who are naïve to DTC 
marketing of medications relative to their American counterparts, and among those 
participants who consume less American media.   
Aim 4 (Exploratory) 
 Exploratory analyses examined whether viewing the PT campaigns would reduce 
stigma-related beliefs about obtaining psychological treatment for mental disorders.   
Hypothesis 4 (Exploratory) 
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It was hypothesized that both the PT and PT-MSE campaigns and the MED 
campaign would significantly reduce self-reported stigma about seeking psychological or 
psychopharmacological treatment for mental health difficulties, relative to NEU.   
Method 
Research Design  
This project utilized a randomized control trial design.  Participants were 
randomly assigned to view one of four commercial campaigns via the Internet on three 
occasions.  Each campaign consisted of three different commercials embedded within 
unrelated content (i.e., other commercials and a comedic television episode).  
Specifically, participants were randomly assigned to consume either the: [1] 
psychological treatment campaign (e.g., the “Psychotherapy can help” campaign); [2] 
psychological treatment informing about medication side effects campaign (PT-MSE; 
e.g., the “Psychotherapy works without side effects” campaign); [3] medication campaign 
(MED; e.g., “many medications can help you feel better”); or [4] neutral campaign, 
consisting of commercials unrelated to mental health [NEU].  The four campaigns were 
equal in length.  All four groups of participants viewed the video campaigns, embedded 
within unrelated content, via the Internet three times (once per week for three consecutive 
weeks).  Prior to the intervention (T1), one week following the final viewing (T2), and 
three months after the final viewing (T3), data regarding attitudes and behaviors relative 
to seeking treatment were collected. 
Independent variables.  The experimental manipulation of randomly assigned 
advertisement campaigns constituted the primary independent variable (i.e., assignment 
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to PT, PT-MSE, MED, or NEU).  To enhance external validity and make these 
campaigns similar to real-world DTC marketing campaigns, for each viewing session 
videos were embedded within approximately 15 minutes of distracter material (i.e., 
between clips from a television show and other unrelated advertisements).  In line with 
typical DTC advertisements for pharmaceutical treatments for mental disorders, each 
video was approximately thirty seconds long.  Given the importance of repetition for 
effective advertising (e.g., Lane, 2000), the 30-second advertisement, embedded within 
approximately 15-minutes of unrelated viewing material, was presented a total of nine 
times to each participant (three times throughout each of the three viewing sessions, 
which occurred over the course of three weeks).   
Dependent variables.  Dependent variable data were collected at baseline (T1), 
one week following the final viewing session (T2), and at a three-month follow-up (T3). 
The primary dependent variables of interest were the rates of treatment-seeking behavior 
within and between groups, intention to seek treatment, and attitudes about psychological 
treatments and psychopharmacological interventions.  These variables were assessed via 
a face-valid questionnaire.   
Data regarding demographic characteristics including age, race/ethnicity, marital 
status, gender, self-reported mental health status, stigma-related beliefs about utilizing 
psychological treatments, DSM-IV symptomatology and socio-economic status were also 
collected.  
Participants  
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 The sample consisted of 344 adults age 18 and over who were taking a 
psychology course at Boston University or Ryerson University.  258 (75.0%) of 
participants were female, and 213 (61.9%) were from Boston University.  The mean age 
of the sample was 18.56 (SD=2.79). The racial/ethnic identities reported by participants 
were as follows: non-Hispanic Caucasian (48.5%), Asian (24.1%), Other (17.2%), 
Hispanic (5.2%), Black (3.8%), Pacific Islander (0.9%), and Native American (0.3%). 
95.8% of the sample reported on their family’s annual income.  38.2% of that sample 
reported a family income of below $50,000, 33.9% reported a family income of $50,001-
$100,000, and 27.9% reported a family income of $100,001 or above.  93.6% of the 
sample reported their marital status as single.  11.3% of the sample reported a past or 
present diagnosis of a mental disorder.  
An additional 288 participants consented to participate in the study but did not 
participate after the baseline data collection point.  For 278 (96.5%) of those participants, 
department rules limited the number of studies in which they could participate per 
semester, and they did not have enough remaining study participation slots remaining at 
the time of signing up for the present study. The present analyses were conducted on the 
344 participants who consented who had an opportunity to participate in the full study 
(i.e., consenting participants who for departmental reasons were unable to participate in 
full were not included in the present analyses).     
Recruitment and payment of participants.  Undergraduate participants were 
recruited via university psychology departments at Boston University and Ryerson 
University. Participants received course credit for approximately 25 minutes of their time 
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on three occasions and approximately 10 minutes each on a fourth and fifth occasion.  To 
encourage completion of T1-T3, participants were entered into a lottery for $100 after 
completing all data collection points.    
Manner of presenting the intervention and collecting data 
 The Internet provides an efficient, resource-effective, and cost-effective means for 
conducting research projects and collecting data, and also provides an ecologically valid 
delivery method, given that individuals are increasingly confronted with marketing 
campaigns in online formats while consuming online media content.  
Online consent and self-report data collection.  Participants signed up for the 
study online, and then received instructions for participation with a link to an online 
consent form and self-report questionnaires on the web service Survey Monkey 
(www.SurveyMonkey.com).  Each participant was assigned a study identification number 
so that identified information was not associated with research data.   
Video hosting website.  The video advertisement campaigns and the content in 
which they were embedded were hosted on YouTube (www.youtube.com), a free video 
hosting website.  The videos were unlisted, meaning that only people who had the link to 
the video could access it.  Participants were provided with the video links via the Survey 
Monkey website. 
Marketing campaign conditions. Those randomized to the PT marketing 
campaign viewed information presented via audio-visual recording about psychological 
treatments, with attention given to the broad empirical support for various mental 
disorders (i.e., “Psychotherapy can help”).  Those randomized to the PT-MSE campaign 
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viewed information presented via audio-visual recording, with attention given to the 
broad empirical support for various mental disorders, along with information about 
potential harmful or uncomfortable side effects of psychopharmaceutical interventions 
(i.e., “Psychotherapy works without side effects”).  Those assigned to the MED campaign 
viewed an advertising campaign that was similar to frequently televised pharmaceutical 
advertisements that have information about the potential benefits of medications.  Those 
assigned to the neutral campaign viewed only the content that did not contain mental 
health related advertising or content (i.e., advertisements for pizza and cars, and comedic 
television episodes).  See Appendix D for scripts for each condition and web addresses 
where the campaign videos can be viewed.    
Measures 
Participants completed a baseline assessment consisting of self-report 
questionnaires (Appendix C).  The same data were collected at T1, T2, and T3.   
Demographic information.  Data on demographic characteristics including age, 
race/ethnicity, marital status, gender, educational attainment, self-reported mental health 
status, and socio-economic status were collected via self-report at T1 (see Appendix A).   
DSM-IV symptomatology.  DSM-IV symptomatology was measured using the 
Depression Anxiety Stress Scales (DASS; see Appendix B), a 42-item questionnaire that 
assesses three negative emotional states (i.e., depression, anxiety, and stress/tension; 
Lovibond & Lovibond, 1995).  The DASS has shown favorable reliability and validity 
(Antony, Bieling, Cox, Enns, & Swinson, 1998; Brown, Chorpita, Korotitsch, & Barlow, 
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1997; Clara, Cox, & Enns, 2001; Page, Hooke, & Morrison, 2007) as well as good 
reliability in clinical and community samples (Antony et al., 1998; Page et al., 2007). 
Treatment-seeking behavior and intention to seek treatment.  Prior to the 
intervention (T1), one week following the final viewing (T2), and three months after the 
final viewing (T3), rates of intended action to seek treatment and rates of obtaining 
psychological treatments were measured.  In a self-report measure adapted from the 
National Comorbidity Survey Replication (NCS-R; http://www.hcp.med.harvard.edu/ncs/ 
replication.php), each participant reported on his or her intentions or lack thereof to seek 
psychological treatment for himself or herself, a family member, or another person (see 
Appendix C).  Participants were also asked whether they had ever sought treatment for a 
psychological condition for themselves, a family member, or someone else, and if so, 
when they sought the services (see Appendix C).  
Attitudes about psychological treatments and medication.  Participants’ 
attitudes were assessed via questions adapted from the NCS-R (Mojtabai, 2007).  
Attitudes toward mental health treatment-seeking were assessed with the following 
questions: (1) “If you had a serious emotional problem, would you definitely get 
psychotherapy, probably get psychotherapy, probably not get psychotherapy, or definitely 
not get psychotherapy?” (2) “How comfortable would you feel talking about personal 
problems with a psychotherapist—very comfortable, somewhat comfortable, not very 
comfortable, or not at all comfortable?”  (3) “Of the people who get psychotherapy for 
serious emotional problems, what percent do you think are helped?” (4) “If you had a 
serious emotional problem, would you definitely take medication, probably take 
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medication, probably not take medication, or definitely not take medication?” (5) “How 
comfortable would you feel taking medication for a serious emotional problem—very 
comfortable, somewhat comfortable, not very comfortable, or not at all comfortable?” 
and (6) “Of the people who take medication for serious emotional problems, what percent 
do you think are helped?”  
Perceived stigma.  The perception of being stigmatized was assessed utilizing an 
additional question from the NCS-R (Mojtabai, 2007).  Specifically, participants were 
asked: “How embarrassed would you be if your friends knew you were getting 
professional help for an emotional problem—very embarrassed, somewhat embarrassed, 
not very embarrassed, or not at all embarrassed?”  
Measure of American media consumption. Participants were asked two 
questions about their consumption of American media: “On average, how many hours per 
week do you spend watching American television stations?” and “How many U.S. 
publications do you read regularly?” These questions were of interest given the 
differences in DTC marketing regulations in the U.S. (where pharmaceutical 
advertisements are minimally regulated) and Canada (where such advertisements are 
highly regulated).  
Data Analytic Strategy   
Change scores from baseline to post-intervention, and from baseline to follow-up 
point, were the data of interest.  All statistical analyses were run using SPSS Version 21 
(SPSS, 2012).  Preliminary analyses were conducted to examine the data for differences 
on demographic variables between the experimental groups.  To examine changes across 
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conditions over time, ANCOVAs examining T2 and T3 data as dependent variables after 
controlling for T1 data were conducted (Rausch, Maxwell, & Kelley, 2003).  Significant 
omnibus tests were followed-up with Bonferonni-adjusted contrasts.  For categorical 
variables, chi-square tests were performed examining associations between condition and 
status of the categorical variable (i.e., moved in the hypothesized direction or not) at T2 
and T3.   
Hierarchical linear regressions (for continuous variables) and logistic regressions 
(for categorical variables) were performed to examine hypothesized moderation effects.  
Each model consisted of two levels: (1) main effects [campaign condition assignment and 
proposed moderator] entered into level one separately and (2) main effects and the 
interaction term [main effects and interactive (product term) effect of moderator X 
treatment assignment] entered into level two (Baron & Kenny, 1986).  In the event of a 
significant interaction, post hoc analyses were conducted to reveal the nature of the 
interaction.   
Results 
Random Assignment Evaluation 
 84 (24.4%) of the participants were randomly assigned to the NEU condition, 82 
(23.8%) to the MED condition, 98 (28.5%) to the PT condition, and 80 (23.3%) to the 
PT-MSE condition. (See Figure 1 for data regarding participant randomization and 
retention). 
Post-randomization.  To evaluate the successfulness of random assignment, 
initial differences between the four condition groups were evaluated.  Chi-squares and 
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one way Analyses of Variance (ANOVAs) indicated that the NEU group, the MED 
group, the PT group, and the PT-MSE group did not differ significantly on any basic 
demographic factors.  Gender was similar across the four groups; χ2  (3, N = 342) = 2.82, 
p =.42.  The four groups did not differ significantly on self-reported family income [F(3, 
326) = 0.89, p = .45] or age [F(3, 339) = 0.29,  p =.84].  Self-reported mental health 
status did not significantly differ across groups χ2 (3, N = 343) = 6.94, p =0.07.  
Participants in the four groups also had similar scores on the DASS at baseline [F(3, 339) 
= 0.40, p =.76].   
Assessment of study completers vs. ineligible noncompleters.  In addition to 
the 344 study participants, an additional 288 potential participants consented to 
participate in the study but did not participate after baseline.  278 (96.5%) of these 
noncompleters may not have been permitted to participate in the study due to rules in 
their psychology department; specifically, if they did not have enough available study 
participation slots remaining due to having participated in other studies through their 
university’s psychology department.   
ANOVA and chi-square analyses were utilized to assess for any significant 
differences at baseline between study completers, (i.e., participants who completed T2 
and/or T3) and those who only completed T1 measures but were ineligible or did not 
continue with participation (study non-completers). Self-reported mental health status did 
not significantly differ between completers and noncompleters χ2 (1, N = 630) = 0.43, p 
=.51 and participants in the two groups also had similar scores on the DASS at baseline 
F(1, 627) = 2.27, p =.13.  A chi-square test showed that the two groups did not differ on 
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whether they had considered obtaining psychological treatment in the past year [χ2 (1, N 
= 559) = 0.34, p =.56].  Independent samples t-tests were conducted to compare key 
dependent variables at baseline in the completers versus noncompleters.  The two groups 
did not differ in their reports of the likelihood that they would take psychotropic 
medication if needed (completers: M=2.42, SD=0.85; noncompleters: M=2.47, SD 0.81) 
t(630)=-0.66, p = .51 or that they would seek psychological treatment if needed 
(completers: M=2.16, SD=0.79; noncompleters: M=2.16, SD 0.79)  t(630)=-0.01 p = .99.  
The lack of baseline differences between the participants who completed the protocol and 
those who did not complete the protocol allowed for missing data to be treated as missing 
at random in subsequent analyses. 
Data Screening 
 Before conducting the analyses to examine study hypothesis, continuous 
dependent variables were assessed for outliers, skewness, and normality.  No outliers 
were found, and the data in all cases were sufficiently normal and unskewed.  Raw 
means, standard deviations, and ranges for the various continuous dependent variables 
were calculated for T1, T2, and T3 data (Table 1). 
Aim 1 
 The primary aim of this project is to investigate the effects of direct-to-consumer 
(DTC) marketing for psychological treatments on (1a) considered, (1b) intended, and (1c) 
actual psychological treatment-seeking behavior for oneself, as well as on (1d) 
considered, (1e) intended, and (1f) actual psychological treatment-seeking behavior for 
another person (i.e., a friend, family member, or another person who is close to the 
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participant). See Table 2 for the raw frequencies for the measures intended and actual 
treatment-seeking behavior.  
Effect of campaign assignment on considering psychological treatment for 
oneself.  Those in the PT-MSE condition were more likely to have newly considered 
psychological treatment for themselves at T2 or T3 than those in the other three 
conditions (aim 1a) χ2(1, N = 176) = 4.74, p = .03.   
Effect of campaign assignment on intended psychological treatment seeking 
for oneself.  Regarding aim 1b, the percentage of participants who newly intended 
psychological treatment at T2 or T3 differed by condition, with those in the PT condition 
more likely to intend to receive psychological treatment than those in the other three 
conditions. χ2(1, N = 309) = 4.20 p = .04.   
Effect of campaign assignment on obtaining psychological treatment for 
oneself.  To address aim 1c, it was determined whether those participants who had not 
reported receiving psychological treatment at baseline had received psychological 
treatment by the end of their study involvement.  A chi-square analysis was utilized for 
the portion of the sample that had not already been receiving psychological treatment at 
baseline.  The analysis demonstrated that the percentage of participants who sought new 
psychological treatment after T1 but before T2 or T3 did not differ by condition, χ2(3, N 
= 233) = 1.20, p = .75.   
Effect of campaign assignment on considering psychological treatment for 
another person.  Changes in consideration of psychological treatment for another person 
did not differ by condition (aim 1d) χ2(3, N = 124) = 4.76, p = .19. 
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 Effect of campaign assignment on intended psychological treatment seeking 
for another person.  Regarding whether the rates of intended treatment-seeking for 
another person (e.g., a friend or family member) differed by condition (aim 1e), chi-
square analyses indicated that the percentage of participants who intended to seek new 
psychological treatment for another person did not differ by condition χ2(3, N = 276) = 
1.89 p = .60.   
Effect of campaign assignment on obtaining psychological treatment for 
another person.  Percentages of actual treatment seeking for another person (aim 1f) also 
did not differ by condition χ2(3, N = 179) = 2.37, p = .50.  
Aim 2 
A secondary aim was to evaluate potential moderators of the association between 
campaign assignment and intended and actual treatment-seeking behavior.  To examine 
each potential moderator, hierarchical logistical regressions were conducted in which 
campaign assignment (i.e., represented by dummy codes) and the proposed moderator 
(DSM-IV symptomatology as measured by the DASS, self-reported stigma about 
receiving mental health treatment, consumption of American media, or country/school) 
were entered as predictors of intended treatment and obtained treatment, as well as the 
product term of campaign assignment X the proposed moderator.   
Predictors of consideration of seeking treatment. To examine predictors of 
considered treatment-seeking, dummy codes for campaign assignment were entered for 
all models into the first block, accounting for approximately 5-8% of the variance 
(Nagelkerke R2 = .049-.079; χ2 (3) = 4.54-5.90, p = .12-.21).  Next, for each model the 
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proposed moderator (i.e., DSM-IV symptomatology as measured by the DASS, self-
reported stigma about receiving mental health treatment, consumption of American 
media, or country/school) was added in the second block.  These additions accounted for 
5-6% of the variance for across proposed moderators (R2 = .051-.127; χ2 (4) = 4.71-9.65, 
p = .05-.32; see Tables 3-6).  Block 2 results suggest that none of the proposed predictors 
contribute a significant main effect in the prediction of considering treatment.  Finally, 
for all models the product term of condition assignment X the proposed moderator was 
added in the third block.  Across interaction terms, this third step including the interaction 
term did not add a significant contribution to the overall model, suggesting none of the 
proposed moderators systematically predicted differential rates of considered treatment 
across conditions. 
Predictors of new intention to seek treatment. To examine predictors of 
intended treatment-seeking, dummy codes for campaign assignment were entered for all 
models into the first block, accounting for approximately 3-5% of the variance 
(Nagelkerke R2 = .027-.051; χ2 (3) = 6.26-9.20, p = .03-.10).  Next, for each model the 
proposed moderator (i.e., DSM-IV symptomatology as measured by the DASS, self-
reported stigma about receiving mental health treatment, consumption of American 
media, or country/school) was added in the second block.  These additions accounted for 
5-6% of the variance for across proposed moderators (R2 = .049-.067; χ2 (4) = 7.92-10.65, 
p = .03-.10; see Tables 7-10).  Block 2 results suggest that only being in the PT condition, 
but no other predictors, contributed a significant main effect in the prediction of intended 
treatment.  Finally, for all models the product term of condition assignment X the 
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proposed moderator was added in the third block.  Across interaction terms, this third 
step including the interaction term did not add a significant contribution to the overall 
model, suggesting none of the proposed moderators systematically predicted differential 
rates of intended treatment across conditions. 
Predictors of obtaining new treatment.  To examine predictors of obtaining 
new treatment, dummy codes for campaign assignment were entered for all models into 
the first block, accounting for approximately 1% of the variance (Nagelkerke R2 = .011; 
χ2 (3) = 0.65-0.68, p = .88-.89).  Next, for each model the proposed moderator (i.e., 
DSM-IV symptomatology as measured by the DASS, self-reported stigma about 
receiving mental health treatment, consumption of American media, or country/school) 
was added in the second block.  These additions accounted for 1-4% of the variance for 
across proposed moderators (R2 = .011-.041; χ2 (3-4) = 0.65-2.44, p = .66-.93; see Tables 
11-14).  Block 2 results suggest that none of the proposed predictors contribute a 
significant main effect in the prediction of obtaining new treatment.  Finally, for all 
models the product term of condition assignment X the proposed moderator was added in 
the third block.  Across interaction terms, this third step including the interaction term did 
not add a significant contribution to the overall model, suggesting none of the proposed 
moderators systematically predicted differential rates of new treatment across conditions. 
Aim 3 
The third aim was to investigate the effects of PT, PT-MSE, and MED campaigns 
on self-reported attitudes towards psychological and pharmacological treatments, as well 
as key moderators of these effects.   
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Main effects of PT, PT-MSE, and MED campaigns on attitudes towards 
treatment. The impact of condition on various aspects of attitude about psychological 
treatment and psychopharmacological treatment was evaluated by performing Analyses 
of Covariance (ANCOVAs) using assignment to one of the four condition groups as a 
between-subjects variables and baseline attitudes as covariates. Analyses indicated that 
the MED condition increased participants’ level of comfort about psychopharmacological 
treatment between T1 and T3 significantly more than the other conditions F(2, 268) = 
7.86, p=.01, η2 = .03 and also increased participants’ willingness to partake in 
psychopharmacological treatment if needed significantly more than the other conditions 
F(2, 271) = 3.86 p =.05, η2 = .014.  Changes in participants’ level of comfort about 
psychological treatment did not differ by condition at T3 F(4, 274) = 1.64, p=.18; nor did 
changes in their reported willingness to partake in psychological treatment if needed F(4, 
274) = 2.12, p=.098.  To further elucidate participants’ beliefs regarding psychological 
and pharmacological interventions, they were asked about the percentage of people 
whom they believed to be helped by receiving either of those interventions.  Changes in 
participants’ beliefs regarding the percentage of people helped by psychological 
treatments [F(4, 271) = 1.35 p=.26] and psychopharmacological interventions [F(4, 270) 
= 0.78, p=.50] did not differ by condition.  See Table 1 for the descriptive statistics for 
the measures of attitude and beliefs about psychological and psychopharmacological 
treatment.  
Predictors of attitudes and beliefs about psychological and 
psychopharmacological treatment. To examine the predictors of changes in [1] 
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reported likelihood of obtaining psychological treatment in the future if needed, [2] 
reported likelihood of obtaining psychopharmacological treatment in the future if needed, 
[3] the percent of people believed to be helped by receiving psychological treatment, and 
[4] the percent of people believed to be helped by receiving psychopharmacological 
treatment, T1 to T3 change scores for each measure of attitude were computed and used 
as the dependent variables. Proposed moderators were (1) DSM-IV symptomatology as 
measured by the DASS, (2) consumption of U.S. media, (3) self-reported stigma about 
receiving mental health treatment, and (4) country/school.   
Predictors of changes in reported likelihood to obtain psychological treatment 
in the future if needed.  DSM-IV symptomatology was examined as a proposed 
moderator of changes in reported likelihood to obtain psychological treatment.  First, the 
main effects of condition assignment (dummy coded) and DASS total score were entered 
as independent variables and the model was found to be nonsignificant F(4, 228) = 1.20, 
p = n.s.  Thus, condition assignment and DSM-IV symptomatology did not significantly 
predict the post-intervention ratings of whether participants would obtain psychological 
treatment if needed.  To test for moderation, interaction terms for condition assignment 
and DSM-IV symptoms were calculated (condition assignment X DASS total score, 
centered) and added to step two of the regression. Entering the interaction between 
condition assignment and total DASS score added a significant contribution to the 
prediction of likelihood to obtain psychological treatment, ΔF(3, 221) = 3.76, p = .01, 
accounting for an additional 6.9% of variance (ΔR2 = .069). Thus, DSM-IV 
symptomatology moderated the relationship between condition assignment and likelihood 
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to obtain psychological treatment if needed.  Specifically, PT-MSE participants with 
lower DASS scores had a significantly increased likelihood to seek psychological 
treatment if needed, whereas those with higher DASS scores reported a decreased 
likelihood of seeking psychological interventions in the future if needed.  No association 
was found for participants in the other three conditions.  Table 15 provides the unadjusted 
and step-by-step statistics of this regression.  Figure 2 provides a graphical representation 
of this moderation effect.  
With regard to the remaining proposed moderators, neither self-reported stigma 
about receiving mental health treatment, nor consumption of U.S. media, nor 
country/school were significant moderators of the relationship between condition and 
change scores of T1 to T3 likelihood to obtain psychological treatment if needed [Model 
1: F(4, 263-297) = 1.01-1.25, p = ns.; Model 2: ΔF(3, 260-294) = 0.67-1.75, p =n.s.] 
Predictors of changes in reported likelihood to obtain psychopharmacological 
treatment in the future if needed. Participants’ T2 and T3 ratings of whether they would 
obtain psychopharmacological treatment in the future if needed was the continuous 
dependent variable, and campaign assignment was the independent variable.   
In step 1 of the regression examining DSM-IV symptomatology as the proposed 
moderator, the main effects of condition assignment (dummy coded) and DASS total 
score were entered as independent variables and the model was found to be 
nonsignificant F(4, 221) = 1.20, p = n.s.  Thus, condition assignment and DSM-IV 
symptomatology did not significantly predict the post-intervention ratings of whether 
participants would obtain future psychopharmacological treatment if needed after 
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accounting for condition assignment.  To test for moderation, interaction terms for 
condition assignment and DSM-IV symptoms were calculated (condition assignment X 
DASS total score, centered) and included in step two of the regression. Entering the 
interaction between condition assignment and total DASS score added a significant 
contribution for those in the PT-MSE condition, ΔF(3, 218) = 2.51, p = .06, accounting 
for an additional 3.8% of the variation (ΔR2 = .038) in whether someone would seek 
future psychopharmacological treatment if needed.  Thus, DSM-IV symptomatology 
moderated the relationship between condition assignment and likelihood of obtaining 
psychopharmacological treatment if needed.  Specifically, PT-MSE participants with 
lower DASS scores had a decreased likelihood to seek psychopharmacological treatment, 
whereas those with higher DASS scores had no change in their likelihood to seek 
psychopharmacological interventions.  No association was found for participants in the 
other three conditions.  Table 16 provides the unadjusted and step-by-step statistics of the 
regression and Figure 3 provides a graphical representation of this moderation effect. 
In step 1 of the regression examining consumption of U.S. media as the proposed 
moderator, the main effects of condition assignment (dummy coded) and total reported 
amount of weekly American consumption of U.S. media were entered as independent 
variables and the model was not found to be significant F(4, 297) = 1.14, p = n.s.  Thus, 
condition assignment and reported amount of weekly consumption of U.S. media did not 
significantly predict the ratings of whether participants reported being willing to obtain 
future psychopharmacological treatment if needed.  To test for moderation, interaction 
terms for condition assignment and consumption of U.S. media were calculated 
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(condition assignment X consumption of U.S. media centered score) and included in step 
two of the regression. Entering the interaction between condition assignment and 
consumption of U.S. media score added a significant contribution in both the PT-MSE 
and MED conditions ΔF(3, 294) = 2.57, p =.05; accounting for an additional 2.5% of the 
variation (ΔR2 = .025).  Thus, for those in the PT-MSE and MED conditions, 
consumption of U.S. media moderated the relationship between condition assignment and 
likelihood to obtain future psychopharmacological treatment if needed.  Specifically, for 
those in the PT-MSE condition, participants with lower consumption of U.S. media had 
no change in their willingness to seek psychopharmacological intervention if needed, 
whereas participants with higher consumption of U.S. media scores were less likely to 
seek future psychopharmacological treatment if needed following the intervention than 
they were at T1.  For the MED condition, participants with lower consumption of U.S. 
media scores were more likely to be willing to seek psychopharmacological intervention 
if needed, where as participants with higher consumption of U.S. media scores were less 
likely to be willing to seek psychopharmacological interventions.   
No association was found for participants in the other two conditions.  Table 17 
provides the unadjusted and step-by-step statistics of the regression and Figure 4 provides 
a graphical representation of this moderation effect. 
With regard to the remaining proposed moderators, neither self-reported stigma 
about receiving mental health treatment nor country/school were significant moderators 
of the relationship between condition and change scores of T1 to T3 likelihood to obtain 
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psychopharmacological treatment if needed. [Model 1: F(4, 264-300) = 0.37-1.00, p = 
n.s.; Model 2: ΔF(3, 261-297) = 0.53-0.74, p =n.s.] 
Predictors of changes in participants’ beliefs about the percent of people helped 
by receiving psychological treatment.  Country was examined as a potential moderator of 
reported changes in participants’ beliefs about the percent of people helped by receiving 
psychological treatment.  The main effects of condition assignment (dummy coded) and 
country were entered as independent variables and the model was not found to be 
significant F(4, 295) = 0.98, p = n.s.  Thus, condition assignment and country did not 
significantly predict post-intervention beliefs about the percentage of people helped by 
psychological treatment.  To test for moderation, interaction terms for condition 
assignment and country were calculated (condition assignment X country) and included 
in step two of the regression.  Entering the interaction between condition assignment and 
school added a significant contribution for those in the PT-MSE condition, ΔF(3, 292) = 
3.14, p = .03, accounting for an additional 3.1% of the variation (ΔR2 = .031) in the belief 
about the percentage of people helped by psychological treatment.  Specifically, 
American participants in the PT-MSE condition showed an increased confidence across 
evaluations in psychological treatments’ ability to succeed in helping people with mental 
disorders, while Canadian participants had decreased confidence across evaluations.  No 
association was found for participants in the other three conditions.  Table 18 provides 
the unadjusted and step-by-step statistics of the regression and Figure 5 provides a 
graphical representation of this moderation effect. 
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With regard to the remaining proposed moderators, neither self-reported stigma 
about receiving mental health treatment, nor consumption of U.S. media, nor DSM 
symptomatology were significant moderators of the relationship between condition and 
change scores of T1 to T3 beliefs about percentages of people helped by psychological 
treatment [Model 1: F(4, 263-266) = 0.68-2.62, p = 0.04-0.73; Model 2: ΔF(3, 260-263) 
= 0.44-1.65, p =n.s.] 
Predictors of changes in participants’ beliefs about the percent of people helped 
by receiving psychopharmacological treatment.  Stigma reported at baseline was 
examined as a potential of changes in participants’ beliefs about the percent of people 
helped by receiving psychopharmacological treatment by condition.  The main effects of 
condition assignment (dummy coded) and reported stigma were first entered as 
independent variables and the model was not found to be significant F(4, 293) = 0.30, p 
= n.s.  Thus, condition assignment and reported stigma did not significantly predict post-
intervention beliefs about the percentage of people helped by psychopharmacological 
treatment.  To test for moderation, interaction terms for condition assignment and stigma 
were calculated (condition assignment X stigma) and included in step two of the 
regression.  Entering the interaction between condition assignment and stigma added a 
significant contribution for those in the PT-MSE condition, ΔF(3, 290) = 3.11 p =.03, 
accounting for an additional 3.5% of the variation (ΔR2 = .035) in the belief about 
percentage of people helped by psychopharmacological treatment.  Specifically, 
participants in the PT-MSE condition with lower reported baseline stigma showed 
decreased confidence across evaluations in psychopharmacological treatments’ ability to 
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succeed, while participants in the PT-MSE condition with higher reported baseline stigma 
had increased confidence across evaluations.  No association was found for participants 
in the other three conditions.  Table 19 provides the unadjusted and step-by-step statistics 
of the regression and Figure 6 provides a graphical representation of this moderation 
effect. 
With regard to the remaining proposed moderators, neither DSM-IV 
symptomatology, nor consumption of U.S. media, nor country/school were significant 
moderators of the relationship between condition and change scores of T1 to T3 
likelihood to obtain psychopharmacological treatment if needed [Model 1: F(4, 262-266) 
= 1.70-2.41, p = n.s.; Model 2: ΔF(3, 259-263) = 1.03-1.92, p = n.s.] 
Aim 4 (Exploratory) 
 Exploratory analyses examined whether viewing the PT campaigns would reduce 
stigma-related beliefs about seeking psychological treatment for mental disorders.   
The impact of condition on self-reported stigma about psychological treatment and 
psychopharmacological treatment was evaluated by performing Analyses of Covariance 
(ANCOVAs) using assignment to one of the four condition groups as a between-subjects 
variables and baseline measurement of stigma as a covariate.  Analyses indicated that 
post-campaign reported stigma did not differ by condition F(3, 270) = .885, p=.45. η2 = 
.10.   
Discussion 
The purpose of the present study was to conduct a preliminary experimental 
investigation of the utility and efficacy of direct-to-consumer (DTC) marketing of 
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psychological treatments (PTs).  An unacceptably low proportion of individuals in need 
seek out mental health services, suggesting that efforts to promote effective mental health 
care need to target the public in addition to professionals.  Most past and current 
dissemination efforts have focused on educating and training providers, which remains a 
crucial—but to date insufficient—part of improving mental health services.  Educating 
consumers about the benefits of psychological treatments may create a pull demand, 
increasing rates of psychological treatments.  Evaluating the efficacy of marketing 
directly to the consumer may therefore help to inform future efforts to increase the use of 
effective psychological treatments.   
Main Findings Regarding Treatment-Seeking Behavior 
In the present study, participants were randomly assigned to view either the 
Psychological Treatment (PT) campaign, the Psychological Treatment informing about 
Medication Side Effects (PT-MSE) campaign, the Medication (MED) campaign, or the 
Neutral (NEU; i.e., control) campaign.  Data regarding attitudes about psychological 
treatment and treatment-seeking behaviors were collected prior to the intervention (T1), 
one week following the intervention (T2), and at a three-month follow-up evaluation 
(T3).  The percentage of participants who newly considered psychological treatment at 
T2 or T3 differed by condition, with PT-MSE participants significantly more likely to 
have considered receiving psychological treatment at T2 or T3 than those in the other 
conditions.  PT participants were significantly more likely to have planned (i.e., intended) 
to receive psychological treatment than those in the other conditions.  Participants did not 
differ by condition with regard to actually obtaining treatment following their viewing of 
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the advertising campaigns.  With regard to attitudes, MED participants, as compared to 
participants in the other conditions, reported significantly increased levels of comfort 
about psychopharmacological treatment at T3.  Baseline reports of DSM-IV 
symptomatology, stigma toward psychological treatments, media consumption, and 
nationality all significantly moderated various outcomes related to attitudes toward 
psychopharmacological and psychological treatment.  These findings suggest that 
increasing consumer knowledge of PTs may be a worthwhile augmentation to traditional 
dissemination and implementation efforts that target mental health providers. 
It was hypothesized that compared to those assigned to the medication campaign, 
those assigned to the psychological treatment marketing campaigns (PT and PT-MSE) 
would report increased rates of intended psychological treatment-seeking.  Regarding this 
hypothesis, the percentage of participants who newly intended psychological treatment 
after the intervention did differ by condition, with those in the PT condition more likely 
to intend to receive psychological treatment than those in the other three conditions.  
While PT individuals were significantly more likely to intend to obtain psychological 
treatment as compared to those in the other conditions, those in the PT-MSE condition 
did not have that same increased likelihood.  This hypothesis was therefore partially 
supported.  However, those in the PT-MSE condition did have an increased likelihood of 
considering psychological treatment for themselves than those in the other three 
conditions.  The differences in outcomes for the PT versus PT-MSE conditions were 
somewhat surprising, as it was hypothesized that the two conditions would have been 
comparable in effecting changes in rates of treatment-seeking behaviors.  One possible 
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explanation is that the PT-MSE advertisements may have been more effective at eliciting 
consideration than the PT advertisements (due to the comparisons made to medication, 
causing the viewer to think about the differences between psychopharmacological and 
psychological treatments) while the PT advertisements were more straightforward, 
perhaps more effectively lending themselves to unbridled intention more than the PT-
MSE advertisements.  
It was also hypothesized that compared to a group of individuals assigned to the 
medication campaign, those assigned to the psychological treatment marketing 
campaigns (PT and PT-MSE) would report increased frequency of obtaining 
psychological treatments at T2 and/or T3.  Contrary to this hypothesis, the percentage of 
participants who sought new psychological treatment did not differ by condition.  Again, 
this could be a result of the relatively low base rate of new psychological treatment that 
would occur in most representative undergraduate samples in a three-month period.  Of 
course, it could also be an indication of the advertisements’ relative inefficacy in 
changing actual behavior.  Further research with a clinical and/or larger sample, and/or 
with more extensive campaigns (e.g., several months) similar to those commonly 
launched by the pharmaceutical industry, would help to elucidate the reasons for this null 
finding.  
Additionally, it was hypothesized that those assigned to the psychological 
treatment marketing campaigns (PT and PT-MSE) would report increased rates of 
intended treatment-seeking and actual psychological treatment-obtaining for someone 
else, (i.e., a friend, family member, or someone else who was close to the participant) 
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following the intervention.  Contrary to expectations, none of the variables related to 
other people differed by condition following the intervention.  One potential explanation 
for this null finding is that the video advertisements did not directly speak about 
recommending or seeking treatment for another person.  With the video scripts directly 
referring to the viewer in the second person, it is less likely that advertisements would 
affect intended or actual treatment seeking on behalf of other persons.  Additionally, the 
questionnaires did not capture an increase in the number of people one was considering 
for psychological treatment (i.e., if a participant was already considering psychological 
treatment for one person, then following the advertising campaigns began considering 
psychological treatment for an additional person, this information would not have been 
captured by the measures).  Therefore, this null finding may have been a result of 
insufficient measurement.  
Findings for Moderator Analyses of Treatment-Seeking Behavior 
 It was hypothesized that reported stigma-related beliefs and DSM-IV 
symptomatology at baseline would each moderate the relationship between DTC 
campaign assignment and intended and actual treatment-seeking behavior.  Specifically, 
it was hypothesized that the increased association between the PT and PT-MSE 
campaigns (relative to the MED and NEU campaigns) and intended and actual 
psychological treatment-seeking behavior would be strongest among individuals with 
lower stigma-related beliefs and higher symptomatology at baseline.  Country and 
American media consumption were also examined as moderators, with experimental 
effects, particularly for the MED condition, hypothesized to be stronger among Canadian 
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participants who were purportedly relatively naïve to DTC marketing of medications 
relative to their American counterparts.   
Somewhat unexpectedly, none of the proposed variables attained significance as 
moderators of intended and actual treatment-seeking behavior between conditions.  It was 
expected that those with lower stigma-related beliefs would be the most strongly 
influenced by the advertisements, but this was not, in fact, the case.  In retrospect, 
perhaps those with lower stigma and higher symptomatology would have been more 
likely to have already considered, intended, or sought psychotherapy, making them 
ineligible to have newly sought psychotherapy over their involvement in the study.  
Running post hoc chi-square analyses revealed that while this was not the case for stigma 
[χ2 (1, N = 342) = 0.02, p =.88] it was the case for DSM-IV symptomatology [χ2 (1, N = 
343) = 5.56, p =.02], with those with higher scores on the DASS already having 
considered, intended, or sought psychotherapy at T1 than those with lower DASS scores.  
With regard to country and media consumption as proposed moderators, it turns out that 
Canadians’ and Americans’ media consumption was more similar than different.  While 
media consumption did not significantly differ across countries, it did approach 
significance, with Canadians surprisingly reporting higher consumption of American 
media than did American participants, F (1, 338) = 2.93, p = .09.  Additionally, 
commercials in Canada can include the name of the drug but cannot state what it does, 
and commercials that state a medical condition cannot include the name of the product 
(but they can include a URL that would include more information).  So while Canadian 
viewers may be less frequently exposed to the type of pharmaceutical advertisements 
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often seen in the U.S., it is possible that rates are actually similar or that the rates at 
which they are viewed are enough for them to have an effect, even if they are less 
frequently seen than in the U.S.  
Main Findings Regarding Attitudes toward Psychological and Psychopharmaco-
logical Treatments 
 It was hypothesized that compared to groups of individuals in the MED and NEU 
campaigns, respectively, those assigned to the PT campaigns (i.e., PT and PT-MSE) 
would show increased self-reported positive attitudes about psychological treatments, and 
that those in the MED condition would report increased self-reported positive attitudes 
about psychopharmacological treatments. It was also hypothesized that reported stigma-
related beliefs and DSM-IV symptomatology at baseline would each moderate the 
relationship between DTC campaign assignment and attitudes about psychological 
treatments; specifically, that the increased association between the PT campaigns 
(relative to MED and NEU) and positive attitudes about psychological treatments would 
be strongest among individuals with lower stigma-related beliefs and higher 
symptomatology at baseline.  Country and media consumption were also examined as 
moderators, with experimental effects hypothesized to be stronger among Canadian 
participants who may be naïve to DTC marketing of medications relative to their 
American counterparts and those participants who consume less American media.   
With regard to main effects, analyses indicated that being in the MED condition, 
over the other three conditions, significantly increased participants’ level of comfort 
about psychopharmacological treatment and willingness to partake in 
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psychopharmacological treatment if needed.  These main effects were not replicated, 
however, for participants’ level of comfort about psychological treatments and 
willingness to partake in psychological treatment if needed.  Changes in participants’ 
beliefs regarding the percentage of people whom they believed to be helped by 
psychological and psychopharmacological interventions also did not differ by condition.  
Hypotheses regarding main effects of attitudes and beliefs about psychological and 
psychopharmacological treatments were therefore only partially supported.  Only 
participants’ attitudes with regard to medication changed for those in the MED group, 
and not attitudes about psychological treatment for those in the PT and PT-MSE groups.  
This was particularly surprising in light of the results on the categorical measures of 
intended treatment-seeking behavior.  Interestingly, although intention to seek 
psychological treatment and consideration about receiving treatment increased for those 
in PT and PT-MSE, respectively, attitudes did not.  This may point to a potential 
remaining stigma about receiving treatment even when individuals believe that they 
could benefit from it. 
It was hypothesized that both PT campaigns and the MED campaign would 
significantly reduce self-reported stigma about seeking psychological help for mental 
health difficulties, relative to the neutral campaign.  However, analyses indicated that 
reported stigma did not differ by condition.  Given the messages of the commercials, it 
was expected that individuals in the non-control conditions might have had a change in 
their levels of expected embarrassment about receiving psychological treatment.  It is 
highly likely that a more targeted, personalized, or less solitary advertisement campaign 
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would be more effective, given the pervasiveness of stigma toward mental health 
treatment (Evans-Lacko et al., 2012; Rüsch et al., 2005; Wahl, 1999). 
Results of Moderation Analyses for Measures of Attitudes toward Psychological and 
Psychopharmacological Treatments 
Several potential moderators of attitudes and beliefs regarding psychological and 
psychopharmacological treatment were examined.  In one moderation analysis, it was 
found that PT-MSE participants with lower DASS scores had a significantly increased 
likelihood to seek psychological treatment if needed, whereas those with higher DASS 
scores had a decreased likelihood to seek psychological interventions.  While this result is 
somewhat unexpected, it could be explained by those with lower DASS scores not having 
considered treatment before, due to a relative lack of necessity, but upon viewing the 
advertisements they have an increased likelihood to seek treatment if they were to need it.  
In fact, post hoc analyses revealed that those with lower DASS scores at baseline were, in 
fact, less likely to have ever considered treatment before study participation than their 
counterparts with higher DASS scores [χ2 (1, N = 309) = 58.65, p <.001] giving them a 
greater opportunity to shift from not having considered psychological treatment to having 
considered it. 
DSM-IV symptomatology also moderated the relationship between condition 
assignment and likelihood to obtain psychopharmacological treatment if needed.  
Specifically, PT-MSE participants with lower DASS scores had a decreased reported 
likelihood to seek psychopharmacological treatment, whereas those with higher DASS 
scores had no change in their likelihood to seek psychopharmacological interventions. 
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This result was not predicted although not totally surprising.  Given the message of the 
PT-MSE ads (i.e., “psychotherapy can help without side effects”), those who may be 
unlikely to seek any form of treatment anyway given low DSM-IV symptomatology 
would be even less likely to seek psychopharmacological treatment when confronted with 
information about their side effects. 
For those in the PT-MSE and MED conditions, consumption of U.S. media 
moderated the relationship between condition assignment and likelihood to obtain 
psychopharmacological treatment if needed.  Specifically, for those in the PT-MSE 
condition, participants with lower consumption of U.S. media scores had no change in 
their willingness to seek psychopharmacological intervention if needed, whereas 
participants with higher consumption of U.S. media scores were less likely than at 
baseline to seek psychopharmacological treatment if needed.  For those in the MED 
condition, participants with lower consumption of U.S. media scores were more likely to 
be willing to seek psychopharmacological intervention if needed, whereas participants 
with higher consumption of U.S. media scores were less likely to be willing to seek 
psychopharmacological interventions.  With regard to moderation effects in the MED 
condition, a lower consumption of American media means that the study advertisements 
may be more novel to participants, perhaps leading them to be more affected by the 
advertisements’ message, while those with higher consumption of media may have a 
negative reaction to pharmaceutical advertisements due to their proliferation in American 
media.  For those in PT-MSE, results can be considered in this context as well—those 
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with higher media consumption perhaps are particularly savvy about noticing messages 
about the unfavorable side effects of psychopharmaceutical intervention.  
Implications  
Psychological treatments are assuming a less prominent role in mental health care, 
despite tremendous support for their safety and utility, while the use of pharmaceutical 
treatments to treat mental disorders is rising (Olfson & Marcus, 2010).  We are at a 
crucial time in which a great number of effective treatments for mental disorders exist but 
affected individuals are increasingly receiving unsupported treatment regimens, if they 
even seek treatment at all.  The central task of effective dissemination and 
implementation of efficacious psychological treatments is undoubtedly educating and 
training providers.  However, the present findings suggest involving the consumer more 
explicitly may be another potentially useful avenue for promoting psychological 
treatments–one that has shown significant efficacy in neighboring markets.  The present 
findings suggest such a “bottom-up” approach can result in an increased number of 
mental health consumers considering and intending to seek out psychological treatments, 
potentially creating a pull demand for more professionals to be trained in and provide 
PTs.   
In order to increase consumer knowledge of the effectiveness of PTs for treating 
mental disorders, increased funding is necessary, both for research to effectively examine 
the use of DTC advertising of PTs, and for funding advertisements in many forms—
television, print, and Internet (both traditional advertisement formats and grassroots 
advertising formats, such as YouTube videos).  In one example of directing funds toward 
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increasing awareness of psychotherapy, the APA has recently funded a large 
psychotherapy awareness initiative in which they have created advertisements for 
psychotherapy that parody drug advertisements and speak of the utility of psychotherapy 
in treating such disorders as anxiety and depression.    
Matching drug companies’ advertising dollars will not be feasible.  The goal 
should not be to simply compete directly with those efforts, many of which promote the 
safe use of medications that can be quite helpful in the management of mental disorders, 
nor should it be for those whose primary role in the mental health system is to prescribe 
drugs to instead provide PTs.  Rather, the goal should be to complement these efforts in 
order to adequately disseminate important information about PTs—information that at 
present is not sufficiently reaching the public.  With sufficient funding, television 
advertisements about the effectiveness of PTs for mental disorders would be an ideal way 
to reach consumers, given television advertisements’ effectiveness (Rubinson, 2009).  An 
excellent illustration of such efforts is success of the promotion of the Triple P Parenting 
Program in Australia, which teaches parents positive parenting skills to use with children 
who have conduct problems.  A 6-episode series about the Triple P program aired in a 
prime time slot and reached an average of over 4 million viewers per episode, and 
evidence shows that watching the program both with and without augmented materials 
such as a workbook and web support helped reduce disruptive behavior (Sanders, Calam, 
Durand, Liversidge, & Carmont, 2008).   
While matching the pharmaceutical industry’s vast financial resources may not be 
feasible in the current environment, increased funding for DTC advertising of 
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psychological treatments is necessary.  This presents a challenge to secure resources to 
finance this effort.  With the changing health care climate in the United States, increasing 
rates of efficacious, cost-effective treatments such as EBPTs might appeal to lawmakers.  
While the pharmaceutical industry’s influence on Capitol Hill has been well documented, 
efforts should also be made to inform lawmakers about EBPTs clinical utility and cost-
effectiveness.  Moreover, from a public health standpoint, improving mental health 
services in the U.S. and educating consumers about available efficacious treatments is 
increasingly a priority of federal and state agencies that may therefore be interested in 
providing funding for DTC efforts.  Professional organizations, such as the APA and the 
Association for Behavioral and Cognitive Therapies (ABCT), and disease-oriented 
groups, such as the Anxiety and Depression Association of America, have already begun 
to target consumers directly and should continue to do so.  Publishers of treatment 
manuals and self-help books that contain information about mental disorders that are 
informed by research could also benefit by advertising directly to consumers and funding 
such efforts. Finally, interested lay groups, such as nonprofit organizations related to 
mental health (e.g., the National Alliance on Mental Illness), and smaller mental health 
clinics all have a role in the funding for, and dissemination of, DTC campaigns for PTs. 
Even without sizeable funds, grassroots efforts by subject matter experts, 
including practitioners and researchers, have fueled the efforts to educate consumers 
about mental disorders and their treatments.  Using social networking services and video 
hosting sites to spread information about the PTs for mental disorders, as some 
organizations have already, may lead more people into treatment and normalize the 
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experience of mental disorders, thus reducing the stigma of receiving treatment.  Now 
that some nascent efforts have targeted consumers directly, we need empirical 
investigations to clarify the circumstances under which such efforts will be most 
effective.  With knowledge from these investigations put into practice, consumers can be 
armed with knowledge of psychological treatments, in addition to the widespread 
knowledge about the utility of medications, and will be assisted in making informed 
decisions about their mental health care.  
Models from behavioral economics and the practices of the pharmaceutical 
industry can also inform next steps in the DTC advertising of psychological treatments.  
The behavioral economics model of loss aversion demonstrates that, when making 
decisions, individuals have a stronger inclination to avoid loss than to achieve gains 
(Kahneman & Tversky, 1984).  The results from the present study, which were stronger 
in many cases in the PT-MSE condition, may reflect this phenomenon, with certain 
participants seemingly responding to the notion that medication may present unfavorable 
side effects.  In addition to touting the benefits of psychological treatments, it may be 
beneficial for some DTC efforts to focus on potential deleterious effects of the alternative 
treatment mechanism (i.e., psychopharmacological treatments).  Along these lines, an 
effective movement in the late 1980s and early 1990s targeted providers in a campaign to 
teach about the deleterious side effects of certain medications, and succeeded in 
decreasing rates of inappropriate prescribing (Soumerai & Avorn, 1990). 
The pharmaceutical industry’s extraordinarily successful practices may be used as 
a model for initial and continued DTC advertising of psychological treatments.  
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Advertisements in the pharmaceutical industry create selective demand (i.e., for a specific 
drug) rather than primary demand, (i.e., for psychotropic drugs as a whole).  It would be 
prudent for DTC advertisements for PTs to ultimately take this approach as well, so that 
consumers know exactly what treatments may be used for which disorders.  The 
pharmaceutical industry has also, in one of their most profitable practices, utilized 
medication samples (for providers, and hence, to consumers) to increase usage rates of 
specific drugs. Providers of psychological treatments may begin to consider whether this 
would be an ethical and useful practice to increase rates of utilization of PTs as well.  
Product placement (e.g., in television shows) and targeted advertisements (e.g., via 
Internet search engines, such as Google Ads) should also be examined as a potential 
avenue for DTC efforts.  While the current wide reach of the pharmaceutical industry is 
not feasible for DTC marketing of PTs, if advertisements are specific and targeted, 
relevant information may reach the people who stand to benefit from it most (e.g., people 
who are watching certain television shows or who are searching for treatment for mental 
disorders on the Internet).  As the pharmaceutical industry has demonstrated, awareness 
fosters behavior, and frequent, simple, targeted messages (“ask your doctor about…”) are 
often sufficient to change consumer behavior. 
This study demonstrated an ability to affect change in individuals’ considerations 
and intentions to seek psychological treatment, as well as their attitudes toward 
psychological treatment.  Building on this work, future work is now needed to examine if 
DTC advertising can be used to specifically direct the flow of treatment seeking PT 
patients toward EBPTs over unsupported PTs.  Similar to the potential deleterious side 
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effects of off-label uses of psychopharmacological treatments, “off-label” psychological 
treatments can be unproductive and in some circumstances actually harmful (with 
patients facing worse outcomes, iatrogenic effects, lost money, and lost time) on 
unsupported PTs.  Future work in this developing area may provide important directions 
on this front. 
Limitations 
 A review of the literature suggests that this is the first study of its kind.  Despite 
using a randomized controlled design and embedding the DTC campaigns within 
unrelated content similar to the way DTC campaigns are commonly situated in typical 
media presentations, the present study was not without limitations.  With regard to the 
participant population, the sample was comprised of undergraduates, which may be less 
than ideally representative of a community sample with regard to both age and 
educational level.  Additionally, given that the sample were psychology students, they 
may be somewhat savvier about treatments for mental disorders than the general 
population.  Additionally, this study may have yielded different results if done with a 
clinical sample (i.e., individuals who could likely benefit from research), which is an 
important direction for future examination.  Moreover, more females than males 
participated in the research, which could also affect the broad generalizability of the 
findings. 
 Many people receive much of their media (news, television, targeted 
advertisements, etc.) via the Internet.  However, the results of the study of this particular 
advertising campaign, administered over the Internet, may not extend to other media 
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delivery mechanisms, such as print or television. That said, Internet-based DTC of PTs is 
a particularly exciting area for continued research, given the platform’s great potential for 
targeted advertisements, relative to the more inflexible television marketing campaigns. 
Future work may do well to examine how moderators of the impact of DTC can inform 
decisions about how to target different groups of individuals with different forms of DTC 
presentations.   
Given the amount of advertising to which individuals in the U.S. and Canada are 
exposed daily, advertisement fatigue is surely a factor.  While repetition is important, it is 
still possible that individuals “tune out” most advertisements.  In addition, with so many 
advertisements pervading through our daily lives, advertisements have to be more and 
more unique or outrageous to be noticed.  Alternatively, as a preliminary investigation, 
the advertisements in the present study had a much smaller budget than most 
advertisements seen today, perhaps negatively affecting their external validity. 
 The results of the study should also be considered within the context of the 
limitations of the measures.  First, the measures were all face-valid self-report measures.  
Second, the same measures were administered across time points, which may have led to 
practice effects.  Additionally, a limitation to the categorical data was discovered in the 
analysis phase, specifically, that the yes/no categorical measures were not sensitive 
enough to account for any changes in those participants who may have already 
considered treatment in the last year, but newly considered it again during their study 
participation, or who in the past recommended that a family member seek treatment but 
are now considering doing the same for a friend, etc.  Future investigations will need to 
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ensure that these measurements account for such changes.  Finally, a longer follow-up 
would have been helpful to give more time to obtain treatment and also to see if the study 
effects were maintained over time.  
Future Directions 
The results of this investigation raise several questions, and suggest several 
additional avenues for future research.  Firstly, it would be useful to examine different 
types of advertisements, specifically, advertisements with more specific information 
about specific treatment approaches or strategies for different disorders or sets of 
problems.  Different advertisements could be tested against each other, to see which 
advertisements impact which people and which messages resonate for which constructs. 
Additionally, it would be useful to gather qualitative data (e.g., via a focus group) to get 
more in-depth information about consumers’ thoughts and feelings regarding DTC 
advertisements for psychological treatment.  Finally, similar research with a more 
heterogeneous group and/or a clinical sample may yield interesting findings.   
The present study provides supporting evidence of the preliminary utility and efficacy of 
DTC marketing of psychological treatments, suggesting that increasing consumer 
knowledge of PTs may be a worthwhile augmentation to current dissemination and 
implementation efforts.  Much has been written about increasing rates of dissemination 
and implementation of EBPTs, and in turn the adoption of such treatments, by mental 
health providers.  But by increasing rates of consumer adoption, and thus targeting this 
problem from complementary angles, the goal of increasing rates of EBPT use might be 
reached more efficiently and effectively.   
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Table 1 
Descriptive Data for Continuous Dependent Variables by Condition and Overall 
 
Condition T1 T2 T3 
Mean SD Mean SD Mean SD 
Willingness to Get 
PT 
Overall 2.16 0.79 2.20 0.85 2.15 0.81 
NEU 2.10 0.82 2.10 0.78 2.29 0.79 
MED 2.21 0.68 2.14 0.72 2.06 0.77 
PT 2.15 0.87 2.28 0.93 2.03 0.80 
PT-MSE 2.18 0.79 2.28 0.94 2.24 0.87 
Comfort with PT Overall 2.14 0.74 2.15 0.78 2.18 0.80 
NEU 2.18 0.71 2.07 0.67 2.35 0.78 
MED 2.16 0.74 2.20 0.75 2.02 0.66 
PT 2.12 0.79 2.21 0.89 2.17 0.82 
PT-MSE 2.09 0.72 2.11 0.80 2.18 0.89 
Percent Helped 
with PT 
Overall 2.60 0.74 2.63 0.83 2.66 0.75 
NEU 2.69 0.75 2.71 0.75 2.70 0.72 
MED 2.54 0.77 2.58 0.88 2.67 0.70 
PT 2.55 0.71 2.54 0.79 2.52 0.83 
PT-MSE 2.63 0.72 2.73 0.88 2.78 0.73 
Willingness to 
Take Medication 
Overall 2.42 0.85 2.49 0.86 2.42 0.86 
NEU 2.46 0.91 2.45 0.88 2.52 0.86 
MED 2.33 0.79 2.37 0.76 2.17 0.77 
PT 2.45 0.83 2.48 0.85 2.43 0.88 
PT-MSE 2.44 0.88 2.65 0.94 2.52 0.88 
Comfort with 
Medication 
 
Overall 2.53 0.88 2.54 0.88 2.51 0.88 
NEU 2.53 0.93 2.60 0.88 2.66 0.87 
MED 2.44 0.88 2.40 0.87 2.19 0.85 
PT 2.58 0.84 2.54 0.89 2.57 0.84 
PT-MSE 2.56 0.88 2.61 0.89 2.60 0.90 
Percent Helped 
with Medication 
Overall 2.54 0.86 2.53 0.83 2.60 0.84 
NEU 2.53 0.87 2.58 0.76 2.56 0.82 
MED 2.72 0.88 2.59 0.93 2.65 0.92 
PT 2.42 0.90 2.44 0.84 2.53 0.81 
PT-MSE 2.51 0.76 2.52 0.94 2.68 0.83 
Stigma Overall 2.49 0.86 2.52 0.84 2.43 0.82 
NEU 2.50 0.81 2.63 0.77 2.44 0.80 
MED 2.56 0.82 2.58 0.82 2.45 0.74 
PT 2.53 0.96 2.49 0.91 2.40 0.83 
PT-MSE 2.37 0.80 2.39 0.82 2.45 0.91 
Note: (Values for each possible answer are in parentheses). Willingness to Get PT=“If 
you had a serious emotional problem, would you (1) definitely get psychotherapy,  
56 
 
Note to table 1 continued: 
(2) probably get psychotherapy, (3) probably not get psychotherapy, or (4) definitely not 
get psychotherapy?”  Comfort with PT=“How comfortable would you feel talking about 
personal problems with a psychotherapist—(1) very comfortable, (2) somewhat 
comfortable, (3) not very comfortable, or (4) not at all comfortable?”  Percent Helped 
With PT=“Of the people who get psychotherapy for serious emotional problems, what 
percent do you think are helped?” (1) 0-25%, (2) 26-50%, (3) 51-75%, (4) 76-100%. 
Willingness to Take Medication= “If you had a serious emotional problem, would you 
(1) definitely take medication, (2) probably take medication, (3) probably not take 
medication, or (4) definitely not take medication?” Comfort with Medication= “How 
comfortable would you feel taking medication for a serious emotional problem—(1) very 
comfortable, (2) somewhat comfortable, (3) not very comfortable, or (4) not at all 
comfortable?”  Percent Helped With Medication= “Of the people who take medication 
for serious emotional problems, what percent do you think are helped?” (1) 0-25%, (2) 
26-50%, (3) 51-75%, (4) 76-100%.  Stigma=“How embarrassed would you be if your 
friends knew you were getting professional help for an emotional problem—(1) very 
embarrassed, (2) somewhat embarrassed, (3) not very embarrassed, or (4) not at all 
embarrassed?”  
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Table 2 
 
Frequencies for Outcomes of Considered, Intended, and Actual Treatment  
Seeking Behavior 
 
Condition T1 T2 T3 
Yes No Yes No Yes No 
Past Year 
Considered PT 
and/or med 
Overall 127 183 83 183 81 162 
NEU 35 40 25 40 24 34 
MED 31 41 22 38 16 42 
PT 34 57 17 58 18 52 
PT-MSE 27 45 19 47 23 34 
Ever Received 
PT 
Overall 108 234 90 213 77 192 
NEU 31 52 24 47 25 42 
MED 20 61 23 53 14 45 
PT 32 66 21 64 19 57 
PT-MSE 25 55 22 49 19 48 
Intention to seek 
PT 
Overall 18 264 13 224 11 199 
NEU 9 60 5 53 2 47 
MED 4 67 2 57 2 48 
PT 1 76 3 61 4 55 
PT-MSE 4 61 3 53 3 49 
Previous Belief 
that Friend or 
Family Member 
needs PT 
 
Overall 192 114 134 136 115 115 
NEU 60 16 42 24 34 25 
MED 34 35 30 37 25 27 
PT 58 34 36 38 30 32 
PT-MSE 40 29 26 37 26 31 
Ever 
Recommended 
PT for Family or 
Friend 
 
Overall 157 181 123 177 108 162 
NEU 53 28 38 33 36 31 
MED 37 44 32 44 26 35 
PT 38 60 28 56 29 47 
PT-MSE 29 49 44 25 17 49 
Intend to 
Recommend PT 
for Family or 
Friend 
Overall 54 188 45 172 37 159 
NEU 18 41 9 44 11 37 
MED 8 51 10 49 9 40 
PT 16 53 13 40 9 44 
PT-MSE 12 43 13 39 8 38 
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Table 3 
 
Summary of Logistic Regression Analysis for Condition x DSM Symptomatology 
Predicting Consideration of Seeking Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.03 0.85 0.97 -0.09 0.86 0.92 -0.08 0.87 0.92 
PT Dummy code 0.44 0.80 1.55 0.45 0.81 1.57 0.43 0.82 1.53 
PT-MSE Dummy code 1.49 0.75 4.42* 1.62 0.76 5.06* 1.69 0.78* 5.43 
Constant -2.49 0.60 0.83 -2.32 0.61 0.10 -2.33 0.61 0.10 
DASS Score (centered)    0.03 0.02 1.03* 0.03 0.04 1.03 
MED x DASS       <0.01 0.05 1.01 
PT x DASS       -0.03 0.05 0.97 
PT-MSE x DASS       0.03 0.05 1.03 
* p < .05 
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Table 4 
 
Summary of Logistic Regression Analysis for Condition x Stigma Toward Mental Health 
Treatment Predicting Consideration of Seeking Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code 0.00 0.85 1.00 0.02 0.85 1.03 -0.16 0.96 0.85 
PT Dummy code 041 0.74 1.50 0.41 0.74 1.50 0.38 0.77 1.46 
PT-MSE Dummy code 1.19 0.71 3.27 1.20 0.71 3.32 1.24 0.73 3.46 
Constant -2.49 0.60 0.08 -2.49 0.60 0.08 -2.52 0.62 0.08 
Stigma (centered)    0.12 0.29 1.13 0.49 0.89 1.63 
MED x Stigma       -1.06 1.25 0.35 
PT x Stigma       -0.83 1.02 0.44 
PT-MSE x Stigma       0.19 1.02 1.20 
* p < .05 
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Table 5 
 
Summary of Logistic Regression Analysis for Condition x American Media Consumption 
Predicting Consideration of Seeking Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.06 0.85 0.95 -0.04 0.85 0.96 -.71 1.08 0.49 
PT Dummy code 0.36 0.74 1.43 0.35 0.74 1.42 0.21 0.79 1.24 
PT-MSE Dummy code 1.29 0.71 3.28 1.24 0.72 3.44 1.27 0.72 3.55 
Constant -2.46 0.60 0.09 -2.47 0.60 0.09 -2.47 0.61 0.09 
Media consumption (centered)    -0.05 0.09 0.95 -0.05 0.24 0.95 
MED x Media consumption       0.47 0.32 1.60 
PT x Media consumption       -0.17 0.34 0.84 
PT-MSE x Media consumption       -0.15 0.29 0.86 
* p < .05 
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Table 6 
 
Summary of Logistic Regression Analysis for Condition x Country Predicting 
Consideration of Seeking Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.03 0.85 0.97 0.09 0.86 1.10 -18.74 >100 <0.01 
PT Dummy code 0.39 0.74 1.47 0.47 0.75 1.60 -18.71 >100 <0.01 
PT-MSE Dummy code 1.19 0.71 3.27 1.29 0.72 3.63 -16.86 >100 <0.01 
Constant -2.49 0.60 0.08 -1.67 0.87 0.19 16.81 >100 >100 
School    -0.69 0.55 0.50 -19.01 >100 <0.01 
MED x Country       18.59 >100 >100 
PT x Country       18.86 >100 >100 
PT-MSE x Country       16.80 >100 >100 
* p < .05 
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Table 7 
 
Summary of Logistic Regression Analysis for Condition x DSM Symptomatology 
Predicting Intention to Seek Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code 1.03 0.61 2.79 1.02 0.61 2.27 1.13 0.69 3.1 
PT Dummy code 1.25 0.63 3.48* 1.25 0.63 3.48* 1.38 0.77 3.99 
PT-MSE Dummy code 0.13 0.79 1.13 0.12 0.79 1.13 0.47 0.88 1.61 
Constant -2.79 0.52 0.06 -2.77 0.52 0.06 -2.95 0.59 0.05 
DASS Score (centered)    0.01 0.01 1.01 0.04 0.02 1.04 
MED x DASS       -0.05 0.03 0.95 
PT x DASS       -0.01 0.03 1.00 
PT-MSE x DASS       -0.04 0.04 0.96 
* p < .05 
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Table 8 
 
Summary of Logistic Regression Analysis for Condition x Stigma Toward Mental Health 
Treatment Predicting Intention to Seek Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code 1.06 0.61 2.88 1.10 0.61 3.00 1.11 0.63 3.03 
PT Dummy code 1.26 0.58 3.52* 1.28 0.59 3.61* 1.28 0.61 3.60* 
PT-MSE Dummy code 0.00 0.73 1.00 -0.02 0.73 0.98 0.02 0.76 1.02 
Constant -2.80 0.52 0.06 -2.83 0.52 0.06 -2.85 0.54 0.06 
Stigma (centered)    -0.26 0.21 0.77 -0.32 0.71 0.73 
MED x Stigma       0.28 0.82 1.32 
PT x Stigma       -0.05 0.77 0.95 
PT-MSE x Stigma       0.16 0.98 1.16 
* p < .05 
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Table 9 
 
Summary of Logistic Regression Analysis for Condition x American Media Consumption 
Predicting Intention to Seek Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code 1.01 0.61 2.75 1.00 0.61 2.72 1.14 0.68 3.12 
PT Dummy code 1.21 0.58 3.37* 1.21 0.59 3.36* 1.33 0.66 3.79* 
PT-MSE Dummy code 0.21 0.69 1.23 0.18 0.70 1.21 0.28 0.77 1.32 
Constant -2.77 0.52 0.06 -2.77 0.52 0.06 -2.90 0.60 0.06 
Media consumption (centered)    0.05 0.07 1.05 -0.19 0.28 0.83 
MED x Media consumption       0.22 0.30 1.25 
PT x Media consumption       0.29 0.93 1.34 
PT-MSE x Media consumption       0.29 0.88 1.34 
* p < .05 
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Table 10 
 
Summary of Logistic Regression Analysis for Condition x Country Predicting Intention to 
Seek Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code 1.04 0.61 2.84 1.05 0.61 2.87 1.43 1.86 4.19 
PT Dummy code 1.25 0.58 3.48* 1.25 0.59 3.52* 1.35 1.79 3.87 
PT-MSE Dummy code 0.21 0.69 1.23 0.22 0.69 1.24 0.01 2.11 1.01 
Constant -2.80 0.52 0.06 -2.73 0.69 0.07 -2.85 1.57 0.06 
Country    -0.06 0.37 0.94 0.04 1.19 1.04 
MED x Country       -0.29 1.37 0.75 
PT x Country        -0.08 1.31 0.92 
PT-MSE x Country       0.14 1.52 1.15 
* p < .05 
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Table 11 
 
Summary of Logistic Regression Analysis for Condition x DSM- Symptomatology 
Predicting New Attainment of Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.91 1.17 0.40 -0.82 1.18 0.44 -1.31 1.18 0.27 
PT Dummy code -0.37 0.93 0.69 -0.41 0.94 0.66 -0.56 1.10 0.57 
PT-MSE Dummy code -0.31 0.93 0.73 -0.35 0.94 0.70 -0.24 1.01 0.79 
Constant -2.94 0.59 0.05 0.59 0.59 0.06 -2.93 0.61 0.05 
DASS Score (centered)    0.01 0.02 1.01 0.03 0.03 1.03 
MED x DASS       -0.06 0.11 0.94 
PT x DASS       0.01 0.04 1.01 
PT-MSE x DASS       -0.06 0.06 0.94 
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Table 12 
 
Summary of Logistic Regression Analysis for Condition x Stigma Toward Mental Health 
Treatment Predicting New Attainment of Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.89 1.17 0.41 -0.09 1.17 0.39 -0.90 1.41 0.41 
PT Dummy code -0.35 0.93 0.70 -0.41 0.94 0.66 -0.14 1.01 0.87 
PT-MSE Dummy code -0.30 0.93 0.74 -0.26 0.94 0.78 -0.71 1.01 0.93 
Constant -2.96 0.59 0.05 -3.00 0.60 0.05 -3.17 0.70 0.04 
Stigma (centered)    0.44 0.44 1.56 0.94 0.77 2.55 
MED x Stigma       -0.16 1.55 0.85 
PT x Stigma       -0.99 1.10 0.37 
PT-MSE x Stigma       -0.70 1.18 0.50 
* p < .05 
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Table 13 
 
Summary of Logistic Regression Analysis for Condition x American Media Consumption 
Predicting New Attainment of Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.91 1.17 0.40 -0.87 1.18 0.42 -1.09 1.35 0.34 
PT Dummy code -0.37 0.93 0.69 -0.37 0.93 0.69 -0.50 1.02 0.61 
PT-MSE Dummy code -0.31 0.93 0.73 -0.29 0.94 0.75 -0.36 0.95 0.70 
Constant -2.94 0.59 0.05 -2.98 0.61 0.05 -2.94 0.59 0.05 
Media consumption (centered)    -0.07 0.17 0.93 0.04 0.20 1.04 
MED x Media consumption       -0.34 0.65 0.71 
PT x Media consumption       -0.19 0.42 0.83 
PT-MSE x Media consumption       -0.15 0.39 0.86 
* p < .05 
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Table 14 
 
Summary of Logistic Regression Analysis for Condition x Country Predicting New 
Attainment of Psychological Treatment 
Variable Model 1 Model 2 Model 3 
 B S.E. OR B S.E. OR B S.E. OR 
MED Dummy code -0.89 1.17 0.41 -0.89 1.17 0.41 n/a n/a n/a 
PT Dummy code -0.35 0.93 0.70 -0.35 0.93 0.70 n/a n/a n/a 
PT-MSE Dummy code -0.30 0.93 0.74 -0.30 0.93 0.74 n/a n/a n/a 
Constant -2.96 0.59 0.05 -2.96 0.59 0.05 n/a n/a n/a 
Country    n/a n/a n/a n/a n/a n/a 
MED x Country       n/a n/a n/a 
PT x Country       n/a n/a n/a 
PT-MSE x Country       n/a n/a n/a 
* p < .05 
n/a: Estimation terminated before this point because parameter estimates changed by 
0.001. 
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Table 15 
 
Summary of Linear Regression Analysis for Condition x DSM-IV  
Symptomatology Predicting Changes in Reported Likelihood of Seeking  
Psychological Treatment if Needed 
Variable Model 1 Model 2 
 B S.E. OR B S.E. OR 
Constant 1.78 0.10  0.18 0.10  
MED Dummy code -0.30 0.15 -0.16* -0.30 0.15 -0.16* 
PT Dummy code -0.19 0.16 -0.09 -0.23 0.15 -0.11 
PT-MSE Dummy code -0.10 0.15 -0.05 -0.17 0.15 -0.09 
DASS Score (Centered) <-0.01 <-0.01 -0.05 -0.01 <-0.01 -0.25 
MED x DASS Score    <-0.01 <-0.01 0.10 
PT x DASS Score    <-0.01 <-0.01 0.06 
PT-MSE x DASS Score    0.02 <-0.01 0.27* 
R2 = 0.02 for Step 1 (p = n.s.), ∆R2= 0.05 for Step 2 (p =0.01) 
* p < .05 
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Table 16 
 
Summary of Linear Regression Analysis for Condition x DSM-IV  
Symptomatology Predicting Changes in Reported Likelihood of  
Seeking Psychopharmacological Treatment if Needed 
Variable Model 1 Model 2 
 B S.E. OR B S.E. OR 
Constant 0.05 0.09  0.05 0.09  
MED Dummy code -0.08 0.13 -0.05 -0.08 0.13 -0.05 
PT Dummy code -0.02 0.14 -0.01 -0.02 0.14 -0.01 
PT-MSE Dummy code <0.01 0.14 <0.01 0.02 0.14 0.01 
DASS Total (Centered) <0.01 <0.01 0.05 <0.01 <0.01 0.09 
MED x DASS    <0.01 <0.01 <0.01 
PT x DASS    <0.01 <0.01 0.08 
PT-MSE x DASS    -0.01 <0.01 -0.17* 
R2 = 0.005 for Step 1 (p = 0.89), ∆R2= 0.033 for Step 2 (p =0.06) 
* p < .05 
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Table 17 
 
Summary of Linear Regression Analysis for Condition x Media  
Consumption Predicting Changes in Reported Likelihood of  
Seeking Psychopharmacological Treatment if Needed 
Variable Model 1 Model 2 
 B S.E. OR B S.E. OR 
Constant 0.00 0.08  <-0.01 0.08  
MED Dummy code <-0.01 0.12 <-0.01 <-0.01 0.12 -0.01 
PT Dummy code 0.01 0.11 <-0.01 0.02 0.11 0.10 
PT-MSE Dummy code 0.20 0.12 0.12 0.20 0.12 1.67 
Media Total (Centered) 0.01 0.02 0.04 -0.06 0.03 0.63* 
MED x Media    0.10 0.04 <-0.01 
PT x Media    0.08 0.04 0.13 
PT-MSE x Media    0.09 0.04 0.17* 
R2 = .015 for Step 1 (p = n.s.), ∆R2= 0.040 for Step 2 (p =0.05) 
* p < .05 
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Table 18 
 
Summary of Linear Regression Analysis for Condition x Country  
Predicting Changes in Belief about Percentage of People Helped by  
Psychological Treatment  
Variable Model 1 Model 2 
 B S.E. OR B S.E. OR 
Constant 0.15 0.16  -0.11 0.29  
MED Dummy code 0.10 0.14 0.06 0.02 0.41 0.01 
PT Dummy code 0.04 0.13 0.02 0.25 0.40 0.13 
PT-MSE Dummy code 0.16 0.14 0.09 1.14 0.41 0.59* 
Country -0.15 0.10 -0.09 0.06 0.22 0.03 
MED x Country     0.04 0.29 0.03 
PT x Country    -0.17 0.28 -0.14 
PT-MSE x Country    -0.75 0.30 -0.55* 
R2 = 0.013 for Step 1 (p =n.s.), ∆R2= 0.031 for Step 2 (p =0.026) 
* p < .05 
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Table 19 
 
Summary of Linear Regression Analysis for Condition x Reported  
Stigma Predicting Changes in Belief about Percentage of People  
Helped by Psychopharmacological Treatment  
Variable Model 1 Model 2 
 B S.E. OR B S.E. OR 
Constant 0.05 0.10  0.08 0.10  
MED Dummy code -0.15 0.14 -0.08 -0.16 0.14 -1.16 
PT Dummy code 0.08 0.14 -0.04 -0.10 0.14 -0.74 
PT-MSE Dummy code -0.05 0.14 -0.03 -0.05 0.14 -0.34 
Stigma 0.02 0.06 0.02 -0.21 0.14 -1.56 
MED x Stigma    0.11 0.18 0.58 
PT x Stigma    0.25 0.17 0.15 
PT-MSE x Stigma    0.52 0.19 0.24* 
R2 = 0.004 for Step 1 (p =0.87), ∆R2= 0.031 for Step 2 (p <=0.027) 
* p < .05 
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Figure 1.  Flow of participants through the trial. 
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Figure 2. DSM-IV symptomatology as a moderator of the association between the 
difference across interventions in reported likelihood to get psychological treatment and 
condition. 
Note. Negative difference scores denote increased likelihood to receive psychological 
treatment; positive scores denote decreased likelihood to receive psychological treatment. 
DSM-IV Symptomatology = DASS Total Score. PT=Psychological treatments campaign; 
PT-MSE= psychological treatments + medication side effects campaign; 
MED=medication campaign; NEU=Neutral campaign, consisting of commercials 
unrelated to mental health.   
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Figure 3. DSM-IV symptomatology as a moderator of the association between the 
difference across interventions in reported likelihood to get psychopharmacological 
treatment and condition. 
Note. Negative difference scores denote increased likelihood to receive 
psychopharmacological treatment; positive scores denote decreased likelihood to receive 
psychopharmacological treatment. DSM-IV Symptomatology = DASS Total Score. 
PT=Psychological treatments campaign; PT-MSE= psychological treatments + 
medication side effects campaign; MED=medication campaign; NEU=Neutral campaign, 
consisting of commercials unrelated to mental health.  
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Figure 4. Media consumption as a moderator of the association between the difference 
across interventions in reported likelihood to get psychopharmacological treatment and 
condition. 
Note. Negative difference scores denote increased likelihood to receive 
psychopharmacological treatment; positive scores denote decreased likelihood to receive 
psychopharmacological treatment.  PT=Psychological treatments campaign; PT-MSE= 
psychological treatments + medication side effects campaign; MED=medication 
campaign; NEU=Neutral campaign, consisting of commercials unrelated to mental 
health.   
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Figure 5. Country as a moderator of the association between the difference across 
interventions in percentage of people believed to be helped by psychological treatment 
and condition. 
Note. Negative difference scores denote a report of a decreased percentage of people 
helped by psychological treatment from T1 to T3.  PT=Psychological treatments 
campaign; PT-MSE= psychological treatments + medication side effects campaign; 
MED=medication campaign; NEU=Neutral campaign, consisting of commercials 
unrelated to mental health.   
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Figure 6. Reported stigma at baseline as a moderator of the association between the 
difference across interventions in percentage of people believed to be helped by 
psychopharmacological treatment and condition. 
Note. Negative difference scores denote a report of a decreased percentage of people 
helped by psychopharmacological treatment from T1 to T3. PT=Psychological treatments 
campaign; PT-MSE= psychological treatments + medication side effects campaign; 
MED=medication campaign; NEU=Neutral campaign, consisting of commercials 
unrelated to mental health.  
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Appendix A 
Demographics Questionnaire 
 
Please answer the following questions. (All information is kept strictly confidential.) 
 
1. AGE  _______ 
 
2. GENDER (CHECK ONE): 
________ Female 
________ Male 
 
3. ETHNICITY: 
_______   Caucasian 
_______    Black 
_______    Hispanic/Latino 
_______    Asian-American 
_______    Native-American 
_______    Pacific Islander 
_______    Other- Please Specify ________________________________ 
 
4. MARITAL STATUS: 
_______   Single 
_______   Married 
_______   Live-in Partner 
_______   Divorced/Separated 
_______   Widowed 
_______   Other 
 
5. EMPLOYMENT STATUS: 
_______   Full-time 
_______   Part-time 
_______   Unemployed 
_______   Disabled 
_______   Retired 
_______   Student 
_______   Other 
 
6. YEARLY INCOME: 
_______   0-$10,000 
_______   $10,001-$15,000 
_______   $15,001-$20,000 
_______   $20,001-$25,000 
_______   $25,001-$30,000 
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_______   $30,001-$40,000 
_______   $40,001-$50,000 
_______   $50,001-$60,000 
_______   $60,001-$70,000 
_______   $70,001-$80,000 
_______   $80,001-$90,000 
_______   $90,001-$100,000 
_______   $100,001-above 
 
7. EDUCATIONAL ATTAINMENT: 
_______   Some high school 
_______   GED or equivalent 
_______   High school graduate 
_______   Some college 
_______   2-year college degree 
_______   4-year college degree 
_______   Masters degree 
_______   Doctoral degree 
 
8. MENTAL HEALTH STATUS: 
_______   Present diagnosis of a mental disorder 
_______   Past diagnosis of a mental disorder, in adulthood 
_______   Past diagnosis of a mental disorder, in adulthood 
_______   Suspected diagnosis of a mental disorder not confirmed by a  
     professional 
_______   No past or present diagnosis of a mental disorder  
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Appendix B 
 
DAS S 
Please read each statement and choose a number 0, 1, 2 or 3 that indicates how much the 
statement applied to you over the past week.  There are no right or wrong answers.  Do 
not spend too much time on any statement. 
 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
1. I found myself getting upset by quite trivial things   0   1   2   3 
2. I was aware of dryness of my mouth     0   1   2   3 
3. I couldn't seem to experience any positive feeling at all   0   1   2   3 
4. I experienced breathing difficulty (e.g., excessively rapid breathing, 0   1   2   3 
breathlessness in the absence of physical exertion)  
5. I just couldn't seem to get going      0   1   2   3 
6. I tended to over-react to situations     0   1   2   3 
7. I had a feeling of shakiness (e.g., legs going to give way)  0   1   2   3 
8. I found it difficult to relax      0   1   2   3 
9. I found myself in situations that made me so anxious I was most 0   1   2   3 
relieved when they ended 
10. I felt that I had nothing to look forward to    0   1   2   3 
11. I found myself getting upset rather easily    0   1   2   3 
12. I felt that I was using a lot of nervous energy    0   1   2   3 
13. I felt sad and depressed       0   1   2   3 
14. I found myself getting impatient when I was delayed in any way 0   1   2   3 
(e.g., elevators, traffic lights, being kept waiting) 
15. I had a feeling of faintness      0   1   2   3 
16. I felt that I had lost interest in just about everything   0   1   2   3 
17. I felt I wasn't worth much as a person     0   1   2   3 
18. I felt that I was rather touchy      0   1   2   3 
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19. I perspired noticeably (e.g., hands sweaty) in the absence of   0   1   2   3 
high temperatures or physical exertion 
20. I felt scared without any good reason     0   1   2   3 
21. I felt that life wasn't worthwhile      0   1   2   3 
22. I found it hard to wind down      0   1   2   3 
23. I had difficulty in swallowing      0   1   2   3 
24. I couldn't seem to get any enjoyment out of the things I did  0   1   2   3 
25. I was aware of the action of my heart in the absence of physical  0   1   2   3 
exertion (e.g., sense of heart rate increase, heart missing a beat) 
26. I felt down-hearted and blue      0   1   2   3 
27. I found that I was very irritable      0   1   2   3 
28. I felt I was close to panic       0   1   2   3 
29. I found it hard to calm down after something upset me   0   1   2   3 
30. I feared that I would be "thrown" by some trivial but unfamiliar task 0   1   2   3 
31. I was unable to become enthusiastic about anything   0   1   2   3 
32. I found it difficult to tolerate interruptions to what I was doing  0   1   2   3 
33. I was in a state of nervous tension     0   1   2   3 
34. I felt I was pretty worthless      0   1   2   3 
35. I was intolerant of anything that kept me from getting on with what  0   1   2   3 
I was doing 
36. I felt terrified        0   1   2   3 
37. I could see nothing in the future to be hopeful about   0   1   2   3 
38. I felt that life was meaningless      0   1   2   3 
39. I found myself getting agitated      0   1   2   3 
40. I was worried about situations in which I might panic and make a  0   1   2   3 
fool of myself 
41. I experienced trembling (e.g., in the hands)    0   1   2   3 
42. I found it difficult to work up the initiative to do things   0   1   2   3 
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Appendix C 
Measure of Treatment-seeking Behavior 
(http://www.hcp.med.harvard.edu/ncs/replication.php) 
Was there ever a time during the past 12 months when you felt that you might need 
to see a professional because of problems with your emotions or nerves?  
A. Yes 
B. No 
C. Don’t know 
 
Did you ever in your lifetime go to see any of these professionals for problems with 
your emotions or nerves?  
A. A psychiatrist  
B. General practitioner or family doctor  
C. Any other medical doctor, like a cardiologist, gynecologist or urologist  
D. Psychologist  
E. Social worker  
F. Counselor  
G. Any other mental health professional, such as a psychotherapist or a mental health   
     nurse  
H. A nurse, occupational therapist, or other health professional  
I. A religious or spiritual advisor like a minister, priest, or rabbi  
J. Any other healer, like an herbalist, chiropractor, or spiritualist  
 
How old were you the first time (you had a session of psychological counseling or 
therapy)?  
_____ years old  
_____don’t know  
 
When was the last time (you had a session of psychological counseling or therapy)? 
A. Past month 
B. 2-6 months ago  
C. 7-12 months ago  
D. more than 12 months ago  
E. don’t know  
 
Do you currently intend to seek treatment with a professional because of problems 
with your emotions or nerves?  
A. Yes 
B. No 
C. Don’t know 
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D. Not applicable (currently in treatment) 
 
Have you ever taken any of the following types of prescription medications under 
the supervision of a doctor for your emotions or nerves?  
A. Sleeping pills or other sedatives (such as Ambien or Sonata)  
B. Anti-depressant medications (such as Prozac or Zoloft)  
C. Tranquilizers (such as Xanax or Ativan)  
D. Amphetamines or other stimulants (such as Ritalin or Dextroamphetamine)  
E. Anti-psychotic medications (such as Haldol or Risperdal)  
 
How old were you the first time (you were given this sort of prescription or 
medicine)?  
______ years old 
______don’t know   
 
When was the last time (you were given this sort of prescription or medicine)? 
A. Past month 
B. 2-6 months ago  
C. 7-12 months ago  
D. more than 12 months ago  
E. don’t know  
 
In general, how satisfied are you with any treatments and services you received 
from mental health professionals in the past 12 months? 
A. very satisfied 
B. satisfied 
D. neither satisfied nor dissatisfied 
E. dissatisfied 
F. very dissatisfied 
 
How long had you been thinking that you needed to see a professional before you 
started treatment?  
_______ Duration;  Select unit of time: days / weeks / months / years / don’t know 
 
Which of these three statements best describes by you previously didn’t want to see 
a professional?  
A. I didn’t think I had a problem  
B. I had a problem, but thought I could handle it on my own  
C. I thought that I needed help but didn’t believe professional treatment would be helpful  
 
Was there ever a time during the past 12 months when you felt that a friend, family 
member, or someone else who is close to you might need to see a professional 
because of problems with his/her emotions or nerves?  
A. Yes 
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B. No 
C. Don’t know 
 
Did you ever in your lifetime recommend that a friend, family member, or someone 
else who is close to you go to see any of these professionals for problems with his/her 
emotions or nerves?  
A. A psychiatrist  
B. General practitioner or family doctor  
C. Any other medical doctor, like a cardiologist, gynecologist or urologist  
D. Psychologist  
E. Social worker  
F. Counselor  
G. Any other mental health professional, such as a psychotherapist or a mental health  
     nurse  
H. A nurse, occupational therapist, or other health professional  
I. A religious or spiritual advisor like a minister, priest, or rabbi  
J. Any other healer, like an herbalist, chiropractor, or spiritualist  
K. Never recommended this to a friend, family member, or someone else who is close to  
     me 
 
Do you currently intend to recommend that a friend, family member, or someone 
else who is close to you receive treatment with a professional because of problems 
with emotions or nerves?  
A. Yes 
B. No 
C. Don’t know 
D. Not applicable (currently in treatment) 
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Appendix D 
 
Medication campaign (MED) advertisement scripts:  
Note: all videos for the MED campaign can be viewed at  
https://www.youtube.com/watch?v=zCsTdhUQvwg  
Advertisement #1: 
Depression.  Anxiety. Insomnia. Anger. Worries. Sadness.  
Everybody needs help sometimes.  You’re not the only one.  Mental health problems are 
more common than most people realize.  Many research studies have shown that 
medication works for treating several common psychological disorders. Ask your doctor 
or insurance company about medication.   
Medication. It can help.  
Advertisement #2: 
Feeling hopeless. Feeling scared. Feeling exhausted. Feeling angry.  Feeling worried. 
Feeling lonely.  
Everyone has these feelings.  Sometimes, feel more of these things than we want to feel.  
If this sounds like you, you can get help. Many research studies have shown that 
medication works for treating several common psychological disorders. Ask your doctor 
or insurance company about medication.  
Medication. It can help.    
Advertisement #3: 
You know it doesn’t have to feel this way. But you just don’t know how to make it better.  
You wonder if you’ll ever feel as happy as you used to.  
Lots of people want to feel better—the way they used to feel. These feelings are more 
common than most people realize.  You’re not the only one.  Many research studies have 
shown that medication works for treating several common psychological disorders. Ask 
your doctor or insurance company about medication.   
Medication. It can help. 
 
Psychological treatment (PT) campaign advertisement scripts: 
Note: all videos for the PT campaign can be viewed at   
https://www.youtube.com/watch?v=JPvC96teVcU 
Advertisement #1: 
Depression.  Anxiety. Insomnia. Anger. Worries. Sadness.  
Everybody needs help sometimes.  You’re not the only one.  Mental health problems are 
more common than most people realize.  Many research studies have shown that 
psychotherapy works for treating several common psychological disorders.  Ask your 
doctor or insurance company about psychotherapy. 
Psychotherapy. It can help.  
Advertisement #2: 
Feeling hopeless. Feeling scared. Feeling exhausted. Feeling angry.  Feeling worried. 
Feeling lonely.  
Everyone has these feelings.  Sometimes, we feel more of these things than we want to 
feel.  If this sounds like you, you can get help. Many research studies have shown that 
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psychotherapy works for treating several common psychological disorders.  Ask your 
doctor or insurance company about psychotherapy.   
Psychotherapy. It can help.    
Advertisement #3: 
You know it doesn’t have to feel this way. But you just don’t know how to make it better.  
You wonder if you’ll ever feel as happy as you used to.  
Lots of people want to feel better—the way they used to feel. These feelings are more 
common than most people realize.  You’re not the only one.  Many research studies have 
shown that psychotherapy works for treating several common psychological disorders. 
Ask your doctor or insurance company about psychotherapy.   
Psychotherapy. It can help. 
 
Psychological treatment informing about medication side effects (PT-MSE) 
campaign 
Note: all videos for the PT-MSE campaign can be viewed at   
https://www.youtube.com/watch?v=fj4PPzc6jEk 
Advertisement #1: 
Depression.  Anxiety. Insomnia. Anger. Worries. Sadness.  
Everybody needs help sometimes.  You’re not the only one.  Mental health problems are 
more common than most people realize.  Many research studies have shown that 
psychotherapy works for treating several common psychological disorders without the 
challenging side effects of medication.  Ask your doctor or insurance company about 
psychotherapy.   
Psychotherapy. It can help.  
Advertisement #2: 
Feeling hopeless. Feeling scared. Feeling exhausted. Feeling angry.  Feeling worried. 
Feeling lonely.  
Everyone has these feelings.  Sometimes, we feel more of these things than we want to 
feel.  If this sounds like you, you can get help. Many research studies have shown that 
psychotherapy works for treating several common psychological disorders without the 
challenging side effects of medication.  Ask your doctor or insurance company about 
psychotherapy.   
Psychotherapy. It can help.    
Advertisement #3: 
You know it doesn’t have to feel this way. But you just don’t know how to make it better.  
You wonder if you’ll ever feel as happy as you used to.  
Lots of people want to feel better—the way they used to feel. These feelings are more 
common than most people realize.  You’re not the only one.  Many research studies have 
shown that psychotherapy works for treating several common psychological disorders 
without the challenging side effects of medication.  Ask your doctor or insurance 
company about psychotherapy.   
Psychotherapy. It can help. 
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Appendix E 
Screen shots from video advertisements 
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psychiatric emergency department, neuropsychological testing, CBT for 
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conferences.  Present monthly video case conferences of CBT cases. 
 
9/11-6/12 Boston University Psychological Services Center 
Position: Clinical Supervisor  
Responsibilities: Served as supervisor for a first-year clinician, which 
included providing weekly supervision and case consultation, live and 
taped observation of therapy sessions, and a weekly didactic seminar on 
supervision models and strategies. 
 
1/08-9/11 Center for Anxiety and Related Disorders (CARD) at Boston 
University 
Position: Pre-doctoral Clinician and Diagnostician 
Responsibilities: Conducted individual and group cognitive behavioral 
therapy with children and adolescents with anxiety and other comorbid 
disorders.  Received clinical supervision multiple times per week. 
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Schedule for the DSM-IV Parent and Child Interviews (ADIS-IV-C/P).  
Participated in Parent-Child Interaction Therapy (PCIT) and Selective 
Mutism didactic trainings. 
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to Risk) Massachusetts Mental Health Center/Beth Israel Deaconess 
Medical Center 
Position: Pre-doctoral clinician and evaluator 
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assessments with teenagers and young adults with early psychosis.  
Received certification to administer the Structured Interview for 
Prodromal Syndromes (SIPS). 
 
5/08-5/11 The Intensive Treatment of Adolescent Panic Disorder and 
Agoraphobia Program at Boston University 
Position: Study clinician           
Responsibilities: Delivered a 20-hour, 8-day cognitive-behavioral 
intervention in an intensive format for adolescents with panic disorder 
with or without agoraphobia. Conducted diagnostic assessments before 
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7/09-7/10 Boston Neuropsychological Services, LLC/Mystic Valley Regional 
Charter School Psychology Department 
Position: Clinician/Evaluator            
Responsibilities: Conducted comprehensive psychoeducational, 
neuropsychological, and/or social-emotional evaluations for students 
grades K-12.  Subsequently wrote reports to help determine eligibility for 
Individualized Education Programs (IEPs) and Section 504 
Accommodation Plans.  Conducted individual therapy sessions with 
children with various presenting problems, including mood disorders, 
anxiety disorders, disruptive behavior disorders, ADHD, and pervasive 
developmental disorders.  Provided weekly consultation to teachers. 
 
9/08-6/09 Psychological Services Center at Boston University 
Position: Clinician and Neuropsychology Trainee           
Responsibilities: Provided cognitive behavioral therapies and conducted 
intake interviews.  Conducted comprehensive neuropsychological exams. 
 
7/08 Summer Treatment Program for Children with Separation Anxiety 
Disorder 
Position: Clinician           
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Responsibilities: Delivered a week-long intensive cognitive-behavioral 
intervention for children with Separation Anxiety Disorder within the 
novel context of a camp-like treatment setting. 
 
7/05-7/07 Judge Baker Children’s Center/Harvard Medical School 
Position: Clinical Interviewer and Group Facilitator          
Responsibilities: Conducted structured interviews with children and 
parents. Co-facilitated cognitive-behavioral intervention groups for middle 
school students with depression. 
 
12/03-6/05 Eating Concerns Hotline and Outreach at Harvard University 
Position: Undergraduate Counselor           
Responsibilities: Counseled and advised undergraduates on issues 
concerning eating disorders and body image.  Planned and executed 
campus outreach events. 
 
6/04-9/04 Waverley Place at McLean Hospital 
Position: Milieu Counselor           
Responsibilities: Worked as a milieu counselor at this community 
outpatient program that offers comprehensive care and support for adults 
with chronic mental illness.  Assisted in the implementation of a weekly 
outing program for members, and then co-facilitated the program.   
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Responsibilities: Completed intensive training in exposure and response 
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RESEARCH EXPERIENCE 
 
6/11-present Direct-to-Consumer Marketing of Psychological Treatments: A 
Randomized Controlled Trial 
Position: Principal Investigator       
Responsibilities: Designed project and oversee all aspects of the study, 
including securing funding, data collection, recruitment, data analyses, and 
publications. 
 
9/07-5/11 The Intensive Treatment of Adolescent Panic Disorder and 
Agoraphobia Program at Boston University 
Position: Graduate Student Research Assistant and Clinician       
Responsibilities: Oversaw data collection.  Participated in national 
publicity efforts for recruitment.  Assisted in treatment protocol revision.   
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6/08-6/11 Computer-based Clinician Training in Cognitive Behavioral Therapy  
for Adolescent Panic Disorder 
Position: Project Director from 7/10-6/11; Graduate Research Assistant 
6/08-7/10 
Responsibilities: Generated written and audio content for a cost-effective, 
computer-based training program for treating adolescent panic disorder 
and agoraphobia with cognitive-behavioral therapy.  Developed outcome 
measures and coding system for randomized controlled trial.   
 
3/09-12/10 Parent and Child Bibliotherapy for Childhood Anxiety Disorders 
Position: Principal Investigator       
Responsibilities: Proposed, designed, and evaluated a bibliotherapy 
protocol for children and parents on a waitlist for cognitive behavioral 
therapy for the child’s anxiety disorder (Funded by the Clara Mayo 
Memorial Fellowship, awarded March 2008.)  
 
7/05-7/07 Judge Baker Children’s Center/Harvard Medical School 
Position: Project Coordinator 2006-2007; Research Assistant, 2005 
Responsibilities: Coordinated and oversaw participants, data collection, 
and data entry for a project that introduced evidence-based treatments and 
assessed outcomes for youth to community clinics and school settings.  
Screened for target problem areas (anxiety, depression, and conduct 
problems) using a structured diagnostic interview and self-report symptom 
inventories. Coordinated trainings for new study clinicians and acted as a 
liaison to community mental health clinics.  Trained new research 
assistants on clinical interviews and study protocols.  
 
2/04-6/05 Harvard Laboratory for Clinical and Developmental Research 
  Position: Research Assistant 
Responsibilities: Administered study protocol for an NIMH-funded study 
on thoughts and behaviors related to suicide and non-suicidal self-injury in 
adolescents. Completed training and attained certification to code five 
minute speech samples (FMSS) to determine presence of expressed 
emotion. Assisted in collecting psychophysiological measurements (i.e., 
skin conductance).  Proposed, designed, and implemented an independent 
study for a senior thesis project on the benefits of a high level of 
physiological arousal when discussing the details of a traumatic event. 
Conducted analyses on data and wrote undergraduate senior thesis. 
 
2/02-5/04 Harvard Laboratory for Developmental Studies 
Position: Research Assistant 
Responsibilities: Participated in research activities focused on infant and 
toddler cognitive development.  Selected as primary research assistant on 
study of language acquisition in toddlers. Administered study protocol, 
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which involved teaching novel adjectives to toddlers and assessing their 
understanding of word usage and extension.   
 
TEACHING EXPERIENCE 
 
1/13 Weill Cornell Medical College: Guest lecturer on transdiagnostic 
approaches to treating emotional disorders for psychology internship 
didactic series 
1/12-5/12 Boston University: Teaching Fellow for undergraduate Introductory 
Psychology  
9/11-12/11 Boston University: Teaching Fellow for undergraduate Abnormal 
Psychology   
10/11  Boston University: guest lecturer on research methods for undergraduate  
Abnormal Psychology course 
4/11 Boston University: guest lecturer on diagnosis, assessment, and clinical 
observation of children for graduate level Introduction to Clinical 
Psychology course. 
8/10-12/10 Harvard University Extension School: Teaching Assistant for  
undergraduate Introductory Psychology  
4/10  Boston University: guest lecturer on assessment and treatment of children  
for graduate level Clinical Interviewing course. 
9/07-5/08 Boston University: Teaching Fellow for undergraduate Introductory  
Psychology  
 
EDITORIAL EXPERIENCE 
 
Journal of Clinical Child and Adolescent Psychology—Invited Reviewer 
Behavior Therapy—Ad Hoc Reviewer; Invited Reviewer 
Cognitive and Behavioral Practice—Ad Hoc Reviewer 
Cognitive Therapy and Research—Ad Hoc Reviewer 
Journal of Clinical Psychiatry—Ad Hoc Reviewer 
Psychological Trauma: Theory, Research, Practice, & Policy—Ad Hoc Reviewer 
